Rashmi Kanagal Shamanna, M.D.

Peer-Reviewed Articles

1. Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
2. Khanlari M, Mo H, Kim DH, Sakhdari A, Young KH, Jain P, Wang M, Li S, Kanagal-Shamanna R, Miranda RN, Vega F, Medeiros LJ, Ok CY. Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features. Am J Surg Pathol 47(8):849-858, 2023. e-Pub 2023. PMID: 37288826.
3. Meredith DM, Cooley LD, Dubuc A, Morrissette J, Sussman RT, Nasrallah MP, Rathbun P, Yap KL, Wadhwani N, Bao L, Wolff DJ, Ida C, Sukhanova M, Horbinski C, Jennings LJ, Farooqi M, Gener M, Ginn K, Kam KL, Sasaki K, Kanagal-Shamanna R, Alexandrescu S, Brat D, Lu X. ROS1 alterations as a potential driver of gliomas in infant, pediatric, and adult patients. Mod Pathol:100294. e-Pub 2023. PMID: 37532182.
4. Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol. e-Pub 2023. PMID: 37515433.
5. Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
6. El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology 55(4):514-524, 2023. e-Pub 2023. PMID: 36933995.
7. Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. e-Pub 2023. PMID: 37183966.
8. Jelloul FZ, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, You MJ, Patel KP, Medeiros LJ, Quesada AE. DDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol. e-Pub 2023. PMID: 37154083.
9. Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol 16(1):44, 2023. e-Pub 2023. PMID: 37131217.
10. Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol 201(3):e25-e29, 2023. e-Pub 2023. PMID: 36951293.
11. Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. PMID: 37196217.
12. Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia. e-Pub 2023. PMID: 37185307.
13. Levy B, Baughn LB, Akkari Y, Chartrand S, LaBarge B, Claxton D, Lennon PA, Cujar C, Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang L, Fang M, Kanagal-Shamanna R, Broach JR. Optical genome mapping in acute myeloid leukemia: a multicenter evaluation. Blood Adv 7(7):1297-1307, 2023. PMID: 36417763.
14. Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Res 127:107044, 2023. e-Pub 2023. PMID: 36801700.
15. Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, Roboz GJ, Sweet K, Miller C, Wennborg A, Hickman DK, Kanagal-Shamanna R, Kantarjian H, Lancet J, Komrokji R, Attar EC, Sallman DA. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol 10(4):e272-e283, 2023. PMID: 36990622.
16. Ramia de Cap M, Wu LP, Hirt C, Pihan GA, Patel SS, Tam W, Bueso-Ramos CE, Kanagal-Shamanna R, Raess PW, Siddon A, Narayanan D, Morgan EA, Pinkus GS, Mason EF, Hsi ED, Rogers HJ, Toth L, Foucar K, Hurwitz SN, Bagg A, Rets A, George TI, Orazi A, Arber DA, Hasserjian RP, Weinberg OK, Pathology Group BM. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leuk Lymphoma 64(5):1-9. e-Pub 2023. PMID: 36960680.
17. Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. e-Pub 2023. PMID: 36951163.
18. Abbas HA, Sun H, Pierce S, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour E, Konopleva M, Short NJ, DiNardo C, Daver N, Ravandi F, Kadia TM. Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. Blood Adv 7(5):828-831, 2023. PMID: 35405739.
19. El Hussein S, Medeiros LJ, Gruschkus SK, Wei P, Schlette E, Fang H, Jelloul FZ, Wang W, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant. Virchows Arch. e-Pub 2023. PMID: 36864257.
20. Thongon N, Ma F, Lockyer P, Baran N, Liu J, Jackson C, Rose A, Wildeman B, Marchesini M, Marchica V, Storti P, Giuliani N, Ganan-Gomez I, Adema V, Qing Y, Ha M, Fonseca R, Class C, Tan L, Kanagal-Shamanna R, Nolasco DB, Cerchione C, Montalban-Bravo G, Santoni A, Bueso-Ramos C, Konopleva M, Lorenzi P, Garcia-Manero G, Manasanch E, Viale A, Chesi M, Colla S. Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma. bioRxiv, 2023. e-Pub 2023. PMID: 36865225.
21. Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2022. PMID: 36458426.
22. Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. e-Pub 2023. PMID: 36683287.
23. Krysiak K, Danos AM, Saliba J, McMichael JF, Coffman AC, Kiwala S, Barnell EK, Sheta L, Grisdale CJ, Kujan L, Pema S, Lever J, Ridd S, Spies NC, Andric V, Chiorean A, Rieke DT, Clark KA, Reisle C, Venigalla AC, Evans M, Jani P, Takahashi H, Suda A, Horak P, Ritter DI, Zhou X, Ainscough BJ, Delong S, Kesserwan C, Lamping M, Shen H, Marr AR, Hoang MH, Singhal K, Khanfar M, Li BV, Lin WH, Terraf P, Corson LB, Salama Y, Campbell KM, Farncombe KM, Ji J, Zhao X, Xu X, Kanagal-Shamanna R, King I, Cotto KC, Skidmore ZL, Walker JR, Zhang J, Milosavljevic A, Patel RY, Giles RH, Kim RH, Schriml LM, Mardis ER, Jones SJM, Raca G, Rao S, Madhavan S, Wagner AH, Griffith M, Griffith OL. CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase. Nucleic Acids Res 51(D1):D1230-D1241, 2023. PMID: 36373660.
24. Cantu MD, Kanagal-Shamanna R, Wang SA, Kadia T, Bueso-Ramos CE, Patel SS, Geyer JT, Tam W, Madanat Y, Li P, George TI, Nichols MM, Rogers HJ, Liu YC, Aggarwal N, Kurzer JH, Maracaja DLV, Hsi ED, Zaiem F, Babu D, Foucar K, Laczko D, Bagg A, Orazi A, Arber DA, Hasserjian RP, Weinberg OK. Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group. JCO Precis Oncol 7:e2200400, 2023. PMID: 36689697.
25. Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24-e34, 2023. e-Pub 2022. PMID: 36402146.
26. Zuo Z, Medeiros LJ, Garces S, Routbort MJ, Ok CY, Loghavi S, Kanagal-Shamanna R, Jelloul FZ, Garcia-Manero G, Chien KS, Patel KP, Luthra R, Yin CC. Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology (Basel) 12(1), 2022. e-Pub 2022. PMID: 36671709.
27. Aitken, MJ, Malaney, P, Zhang, X, Herbrich, SM, Chan, LE, Benitez, O, Rodriguez, AG, Ma, H, Jacamo, RO, Duan, R, Link, T, Kornblau, SM, Kanagal Shamanna, R, Bueso-Ramos, CE, Post, SM. Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing. NAR Cancer 4(4), 2022. PMID: 36518526.
28. Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol 97(12):1599-1606, 2022. e-Pub 2022. PMID: 36117258.
29. Ramia de Cap M, Wu LP, Pihan GA, Narayanan D, Morgan EA, Pinkus GS, Cin PD, Hurwitz SN, Bagg A, Patel SS, Tam W, Ouseph MM, Gagan J, Madanat YF, Siddon A, Raess PW, Rogers HJ, Bueso-Ramos CE, Kanagal-Shamanna R, Kurzer JH, Arber DA, Hasserjian RP, Weinberg OK. NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype. Leuk Res 123:106965, 2022. e-Pub 2022. PMID: 36332291.
30. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):3848-3857, 2022. e-Pub 2022. PMID: 35704787.
31. Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Gañán-Gómez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, Santini V, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G, Blobel GA, Colla S. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. Blood Cancer Discov 3(6):554-567, 2022. PMID: 35926182.
32. Darbaniyan F, Zheng H, Kanagal-Shamanna R, Lockyer P, Montalban-Bravo G, Estecio M, Lu Y, Soltysiak KA, Chien KS, Yang H, Sasaki K, Class C, Ganan-Gomez I, Do KA, Garcia-Manero G, Wei Y. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Exp Hematol 115:44-53, 2022. e-Pub 2022. PMID: 36150563.
33. Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver N, DiNardo CD, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood 140(16):1753-1763, 2022. PMID: 35512188.
34. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
35. Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. e-Pub 2022. PMID: 36087091.
36. Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma 63(13):1-12. e-Pub 2022. PMID: 36089905.
37. Wei Y, Zheng H, Lockyer PP, Darbaniyan F, Li Z, Kanagal-Shamanna R, Soltysiak KA, Yang H, Ganan-Gomez I, Montalban-Bravo G, Chien KS, Do KA, Daver N, Garcia-Manero G. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 63(13):1-11. e-Pub 2022. PMID: 36059252.
38. Yang H, Garcia-Manero G, Sasaki K, Montalban-Bravo G, Tang Z, Wei Y, Kadia T, Chien K, Rush D, Nguyen H, Kalia A, Nimmakayalu M, Bueso-Ramos C, Kantarjian H, Medeiros LJ, Luthra R, Kanagal-Shamanna R. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia 36(9):2306-2316, 2022. e-Pub 2022. PMID: 35915143.
39. Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med 24(9):1991, 2022. PMID: 36063163.
40. Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006-4014, 2022. PMID: 35533262.
41. Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins CA, Jabbour EJ, Medeiros LJ, Bhalla K, Kantarjian HM, Ravandi F, Khoury JD. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood 140(1):58-72, 2022. PMID: 35390143.
42. Smith AC, Neveling K, Kanagal-Shamanna R. Optical genome mapping for structural variation analysis in hematologic malignancies. Am J Hematol 97(7):975-982, 2022. e-Pub 2022. PMID: 35560245.
43. Wei Y, Kanagal-Shamanna R, Zheng H, Bao N, Lockyer PP, Class CA, Darbaniyan F, Lu Y, Lin K, Yang H, Montalban-Bravo G, Ganan-Gomez I, Soltysiak KA, Do KA, Colla S, Garcia-Manero G. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia. e-Pub 2022. PMID: 35697791.
44. Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. e-Pub 2022. PMID: 35690645.
45. Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol. e-Pub 2022. PMID: 35567779.
46. Sakhdari A, Class C, Montalban-Bravo G, Sasaki K, Bueso-Ramos CE, Patel KP, Routbort MJ, Loghavi S, Ok CY, Quesada A, Khoury JD, Konoplev SN, Kantarjian HP, Garcia-Manero G, Medeiros LJ, Kanagal-Shamanna R. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol. e-Pub 2022. PMID: 35504958.
47. Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KP. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res 116:106827, 2022. e-Pub 2022. PMID: 35430388.
48. Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, Chow C, Williams H, Carmody L, Barrow-Laing L, Rieke D, Kreutzfeldt S, Stenzinger A, Tamborero D, Benary M, Rajagopal PS, Ida CM, Lesmana H, Satgunaseelan L, Merker JD, Tolstorukov MY, Campregher PV, Warner JL, Rao S, Natesan M, Shen H, Venstrom J, Roy S, Tao K, Kanagal-Shamanna R, Xu X, Ritter DI, Pagel K, Krysiak K, Dubuc A, Akkari YM, Li XS, Lee J, King I, Raca G, Wagner AH, Li MM, Plon SE, Kulkarni S, Griffith OL, Chakravarty D, Sonkin D. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med 24(5):986-998, 2022. e-Pub 2022. PMID: 35101336.
49. Krysiak K, Danos AM, Kiwala S, McMichael JF, Coffman AC, Barnell EK, Sheta L, Saliba J, Grisdale CJ, Kujan L, Pema S, Lever J, Spies NC, Chiorean A, Rieke DT, Clark KA, Jani P, Takahashi H, Horak P, Ritter DI, Zhou X, Ainscough BJ, Delong S, Lamping M, Marr AR, Li BV, Lin WH, Terraf P, Salama Y, Campbell KM, Farncombe KM, Ji J, Zhao X, Xu X, Kanagal-Shamanna R, Cotto KC, Skidmore ZL, Walker JR, Zhang J, Milosavljevic A, Patel RY, Giles RH, Kim RH, Schriml LM, Mardis ER, Jones SJM, Raca G, Rao S, Madhavan S, Wagner AH, Griffith OL, Griffith M. A community approach to the cancer-variant-interpretation bottleneck. Nat Cancer 3(5):522-525, 2022. PMID: 35624339.
50. Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(5):1097, 2022. PMID: 35484266.
51. Banala C, Brasher WP, Kanagal Shamanna R, Bashoura L, Faiz SA. Consolidative opacity in a patient with acute leukemia. Clin Case Rep 10(4):e05694, 2022. e-Pub 2022. PMID: 35414914.
52. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Research Group MC, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406-415, 2022. e-Pub 2022. PMID: 35074072.
53. El Hussein S, DiNardo CD, Takahashi K, Khoury JD, Fang H, Furudate K, Lyapichev KA, Garces S, Kanagal-Shamanna R, Ok CY, Patel KP, Routbort MJ, Ravandi F, Medeiros LJ, Wang SA, Loghavi S. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 57(3):370-376, 2022. e-Pub 2022. PMID: 34992253.
54. Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
55. Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol 97(3):E100-E102, 2022. e-Pub 2022. PMID: 34989420.
56. Sahajpal NS, Jill Lai CY, Hastie A, Mondal AK, Dehkordi SR, van der Made CI, Fedrigo O, Al-Ajli F, Jalnapurkar S, Byrska-Bishop M, Kanagal-Shamanna R, Levy B, Schieck M, Illig T, Bacanu SA, Chou JS, Randolph AG, Rojiani AM, Zody MC, Brownstein CA, Beggs AH, Bafna V, Jarvis ED, Hoischen A, Chaubey A, Kolhe R, Consortium C. Optical genome mapping identifies rare structural variations as predisposition factors associated with severe COVID-19. iScience 25(2):103760, 2022. e-Pub 2022. PMID: 35036860.
57. Khanlari M, Wang X, Loghavi S, Wang SA, Li S, Thakral B, Bueso-Ramos CE, Yin CC, Kanagal-Shamanna R, Khoury JD, Patel KP, Popat UR, Medeiros LJ, Konoplev S. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. Ann Diagn Pathol 56:151860, 2022. e-Pub 2021. PMID: 34823075.
58. Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol 40(2):202-212, 2022. e-Pub 2021. PMID: 34797699.
59. Swoboda DM, Kanagal-Shamanna R, Brunner AM, Cluzeau T, Chan O, Al Ali N, Montalban-Bravo G, Gesiotto QJ, Gavralidis A, Hunter AM, Lee JH, Kuykendall AT, Talati C, Sweet KL, Lancet JE, Padron E, Hussaini M, Song J, Garcia-Manero G, Komrokji RS, Sallman DA. Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia None(None):None. e-Pub 2022. PMID: 34975158.
60. Kanagal-Shamanna R, Bao H, Kearney H, Smoley S, Tang Z, Luthra R, Yang H, Zhang S, Lin P, Wu D, Medeiros LJ, Lu X. Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia. Leuk Lymphoma:1-11. e-Pub 2021. PMID: 34898335.
61. Kanagal-Shamanna R, Orazi A, Hasserjian RP, Arber DA, Reichard K, Hsi ED, Bagg A, Rogers HJ, Geyer J, Darbaniyan F, Do KA, Devins KM, Pozdnyakova O, George TI, Cin PD, Greipp PT, Routbort MJ, Patel K, Garcia-Manero G, Verstovsek S, Medeiros LJ, Wang SA, Bueso-Ramos C. Correction to: Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. e-Pub 2021. PMID: 34903824.
62. Martinez-Baquero D, Sakhdari A, Mo H, Kim DH, Kanagal-Shamanna R, Li S, Young KH, O'Malley DP, Dogan A, Jain P, Wang ML, McDonnell TJ, Miranda RN, Vega F, Medeiros LJ, Ok CY. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Mod Pathol 34(12):2183-2191, 2021. e-Pub 2021. PMID: 34376807.
63. Tashakori M, Kim DH, Kanagal-Shamanna R, Vega F, Miranda RN, Jain P, Wang M, Medeiros LJ, Ok CY. Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. Hum Pathol 118:60-68, 2021. e-Pub 2021. PMID: 34655612.
64. Young PE, Kanagal-Shamanna R, Hu S, Tang G, Thakral B, Daver N, Issa GC, Medeiros LJ, Konoplev S. Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution. Leuk Res 111:106685, 2021. e-Pub 2021. PMID: 34438119.
65. Kanagal-Shamanna R, Orazi A, Hasserjian RP, Arber DA, Reichard K, Hsi ED, Bagg A, Rogers HJ, Geyer J, Darbaniyan F, Do KA, Devins KM, Pozdnyakova O, George TI, Cin PD, Greipp PT, Routbort MJ, Patel K, Garcia-Manero G, Verstovsek S, Medeiros LJ, Wang SA, Bueso-Ramos C. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol None(None):None. e-Pub 2021. PMID: 34775472.
66. Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol 96(11):1420-1428, 2021. e-Pub 2021. PMID: 34351647.
67. Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only SF3B1 Mutation Involving K700E Independently Predicts Overall Survival in Myelodysplastic Syndromes. Cancer 127(19):3552-3565, 2021. e-Pub 2021. PMID: 34161603.
68. Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer 127(19):3541-3551, 2021. e-Pub 2021. PMID: 34182597.
69. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. PMID: 34110383.
70. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
71. Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia. Transplant Cell Ther. e-Pub 2021. PMID: 34023569.
72. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. e-Pub 2021. PMID: 34007049.
73. Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang M. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun 12(1):2877, 2021. e-Pub 2021. PMID: 34001881.
74. Tang Z, Kanagal-Shamanna R, Tang G, Patel K, Medeiros LJ, Toruner GA. Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia. Leuk Res 108:106616. e-Pub 2021. PMID: 34022744.
75. Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. e-Pub 2021. PMID: 33846541.
76. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. e-Pub 2021. PMID: 33901324.
77. Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol. e-Pub 2021. PMID: 33891709.
78. Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. e-Pub 2021. PMID: 33811786.
79. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer None(None):None. e-Pub 2021. PMID: 33914911.
80. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. e-Pub 2021. PMID: 33793964.
81. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11(3):52, 2021. e-Pub 2021. PMID: 33677472.
82. Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol 192(6):1054-1063, 2021. e-Pub 2021. PMID: 33618432.
83. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
84. Pitel BA, Sharma N, Zepeda-Mendoza C, Smadbeck JB, Pearce KE, Cook JM, Vasmatzis G, Sachs Z, Kanagal-Shamanna R, Viswanatha D, Xiao S, Jenkins RB, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Greipp PT, Baughn LB. Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer J 11(2):18, 2021. e-Pub 2021. PMID: 33563889.
85. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol. e-Pub 2021. PMID: 33491779.
86. Montalban-Bravo G, Darbaniyan F, Kanagal-Shamanna R, Ganan-Gomez I, Class CA, Sasaki K, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien KS, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leuk Res 101:106511. e-Pub 2021. PMID: 33517186.
87. El Hussein S, Khoury JD, Lyapichev KA, Tashakori M, Khanlari M, Miranda RN, Kanagal-Shamanna R, Wang SA, Ahmed A, Mirza KM, Crane GM, Medeiros LJ, Loghavi S. Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience. Mod Pathol. e-Pub 2020. PMID: 33219298.
88. Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol. e-Pub 2020. PMID: 33180322.
89. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. e-Pub 2020. PMID: 33156969.
90. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. e-Pub 2020. PMID: 33119202.
91. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
92. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma:1-5. e-Pub 2020. PMID: 32955970.
93. Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3). Am J Hematol. e-Pub 2020. PMID: 32886803.
94. El Hussein S, Patel KP, Fang H, Thakral B, Loghavi S, Kanagal-Shamanna R, Konoplev S, Jabbour EJ, Medeiros LJ, Khoury JD. Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. Am J Surg Pathol 44(9):1235-1243, 2020. PMID: 32590457.
95. Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol. e-Pub 2020. PMID: 32804409.
96. Furqan F, Watson G, Samaniego F, Fayad LE, Morrison MW, Thompson PA, Steiner RE, Chi L, Dabaja B, Pinnix CC, Neelapu SS, Nastoupil LJ, Strati P. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leuk Lymphoma:1-5. e-Pub 2020. PMID: 32650677.
97. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
98. Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J 10(5):61, 2020. e-Pub 2020. PMID: 32457305.
99. Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. e-Pub 2020. PMID: 32356320.
100. Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv 4(8):1670-1677, 2020. PMID: 32324887.
101. Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol None(None):None. e-Pub 2020. PMID: 32238878.
102. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. PMID: 32191807.
103. Montalban-Bravo G, Class CA, Ganan-Gomez I, Kanagal-Shamanna R, Sasaki K, Richard-Carpentier G, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien K, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia 34(3):872-881, 2020. e-Pub 2019. PMID: 31719677.
104. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia T. Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy. Am J Hematol None(None):None. e-Pub 2020. PMID: 32112433.
105. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482-495, 2020. PMID: 32027746.
106. Chien KS, Class CA, Montalban-Bravo G, Wei Y, Sasaki K, Naqvi K, Ganan-Gomez I, Yang H, Soltysiak KA, Kanagal-Shamanna R, Do KA, Kantarjian HM, Garcia-Manero G. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma:1-7. e-Pub 2020. PMID: 32036728.
107. Sakhdari A, Thakral B, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Luthra R, Medeiros LJ, Wang SA, Patel KP, Ok CY. RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med 9(3):849-858, 2020. e-Pub 2019. PMID: 31804006.
108. Ohanian M, Telouk P, Kornblau S, Albarede F, Ruvolo P, Tidwell RSS, Plesa A, Kanagal-Shamanna R, Matera EL, Cortes J, Carson A, Dumontet C. A heavy metal baseline score predicts outcome in AML. Am J Hematol. e-Pub 2020. PMID: 31944361.
109. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian H, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer None(None):None. e-Pub 2019. PMID: 31742675.
110. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. PMID: 31724006.
111. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
112. Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD. Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. Am J Surg Pathol 43(10):1429-1437, 2019. PMID: 31261288.
113. Jain P, Gu J, Kanagal-Shamanna R, Tang Z, Patel KP, Yao H, Fang L, Bao HY, Liu CH, Lin P, Medeiros LJ, Lu X. Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens. Leuk Res 84:106176, 2019. e-Pub 2019. PMID: 31279181.
114. Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol None(None):None. e-Pub 2019. PMID: 31400013.
115. Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi S. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol 41:38-42, 2019. e-Pub 2019. PMID: 31132650.
116. Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol 186(4):538-548, 2019. e-Pub 2019. PMID: 31115909.
117. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 54(7):1089-1093, 2019. e-Pub 2018. PMID: 30446740.
118. Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol 94(7):757-766, 2019. e-Pub 2019. PMID: 30963592.
119. Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian H, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer 125(13):2233-2241, 2019. e-Pub 2019. PMID: 30861111.
120. Boddu P, Gibbons J, Burger J, Sivina M, Thakral B, Kanagal-Shamanna R, Ferrajoli A. Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases. Leuk Lymphoma 60(6):1568-1571, 2019. e-Pub 2019. PMID: 30632839.
121. Hidalgo-Lopez JE, Kanagal-Shamanna R, Reyes S, Zhao C, Medeiros LJ, Bueso-Ramos CE. Ring sideroblasts in chronic phase of polycythemia vera identifies a subset of patients with an increased risk of progression to blast phase. Ann Diagn Pathol 40:45-48, 2019. e-Pub 2019. PMID: 30928887.
122. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
123. Mallampati S, Duose DY, Harmon MA, Mehrotra M, Kanagal-Shamanna R, Zalles S, Wistuba II, Sun X, Luthra R. Rational "Error Elimination" Approach to Evaluating Molecular Barcoded Next-Generation Sequencing Data Identifies Low-Frequency Mutations in Hematologic Malignancies. J Mol Diagn 21(3):471-482, 2019. e-Pub 2019. PMID: 30794984.
124. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3(6):922-933, 2019. PMID: 30902805.
125. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125(4):559-574, 2019. e-Pub 2018. PMID: 30508305.
126. Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KP. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica 104(2):305-311, 2019. e-Pub 2018. PMID: 30171025.
127. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2018. PMID: 30545576.
128. Patel KP, Ruiz-Cordero R, Chen W, Routbort MJ, Floyd K, Rodriguez S, Galbincea J, Barkoh BA, Hatfield D, Khogeer H, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, DiNardo CD, Luthra R, Medeiros LJ. Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection. J Mol Diagn 21(1):89-98, 2019. PMID: 30577887.
129. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185:852-864, 2019. e-Pub 2019. PMID: 30924136.
130. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma 60(1):37-48, 2019. e-Pub 2018. PMID: 29741984.
131. Shroff GS, Truong MT, Carter BW, Benveniste MF, Kanagal-Shamanna R, Rauch G, Viswanathan C, Boddu PC, Daver N, Wu CC. Leukemic Involvement in the Thorax. Radiographics 39(1):44-61, 2019. PMID: 30620703.
132. Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. Br J Haematol 183(5):831-835, 2018. e-Pub 2017. PMID: 29265180.
133. Chun K, Wenger GD, Chaubey A, Dash DP, Kanagal-Shamanna R, Kanturci S, Kolhe R, Van Dyke DL, Wang L, Wolff DJ, Miron PM. Assessing Copy Number Aberrations and Copy-Neutral Loss-of-Heterozygosity Across the Genome as Best Practice: An Evidence-Based Review from the Cancer Genomics Consortium (CGC) Working Group for Chronic Lymphocytic Leukemia. Cancer Genetics 228:236-250, 2018. PMID: 30554732.
134. Jain P, Kanagal-Shamanna R, Konoplev S, Zuo Z, Estrov Z. Biclonal IGHV-4-34 variant hairy cell leukemia and CLL - successful treatment with ibrutinib and venetoclax. Am J Hematol 93(12):1568-1569, 2018. e-Pub 2018. PMID: 30152528.
135. Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype and TP53 disruption. Hum Pathol 82:215-231, 2018. e-Pub 2018. PMID: 30086334.
136. Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578-587, 2018. e-Pub 2018. PMID: 30175400.
137. Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578-587, 2018. e-Pub 2018. PMID: 30175400.
138. Angelova EA, Medeiros LJ, Wang W, Muzzafar T, Lu X, Khoury JD, Ravandi F, Patel KP, Hu Z, Kanagal-Shamanna R. Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Mod Pathol 31(11):1717-1732, 2018. e-Pub 2018. PMID: 29955146.
139. Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver N, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 Protein Overexpression in De Novo Acute Myeloid Leukemia Patients with Normal Diploid Karyotype Correlates with FLT3 Internal Tandem Duplication and Worse Relapse-Free Survival. Am J Hematol 93(11):1376-1383, 2018. e-Pub 2018. PMID: 30117185.
140. Hidalgo-Lopez JE, Kanagal-Shamanna R, Quesada AE, Gong Z, Wang W, Hu S, Medeiros LJ, Bassett RL, d'Orcy E, Yin CC, Cortes J, Jabbour EJ, Kantarjian HM, Bueso-Ramos CE. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. Cancer 124(19):3849-3855, 2018. e-Pub 2018. PMID: 30321462.
141. Sanz-DePedro M, Wang W, Kanagal-Shamanna R, Khoury JD. Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. Current Hematologic Malignancy Reports 13(6):467-476, 2018. PMID: 30338456.
142. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma 17(9):1-4, 2018. e-Pub 2018. PMID: 29338567.
143. Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol 182(5):718-723, 2018. e-Pub 2017. PMID: 28771675.
144. Iacobucci G. NHS chief tells hospitals to send patients to private providers to cut waiting times. BMJ 362:k3759, 2018. e-Pub 2018. PMID: 30171035.
145. Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv 2(15):1807-1816, 2018. PMID: 30054307.
146. Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol 182(3):404-411, 2018. e-Pub 2018. PMID: 29785709.
147. Roy-Chowdhuri S, Mehrotra M, Bolivar AM, Kanagal-Shamanna R, Barkoh BA, Hannigan B, Zalles S, Ye W, Duose D, Broaddus R, Staerkel G, Wistuba I, Medeiros LJ, Luthra R. Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling. Mod Pathol 31(7):1036-1045, 2018. e-Pub 2018. PMID: 29463880.
148. Gur HD, Loghavi S, Garcia-Manero G, Routbort M, Kanagal-Shamanna R, Quesada A, Khogeer H, Pierce S, Medeiros LJ, Kantarjian H, Khoury JD. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. Am J Surg Pathol 42(6):799-806, 2018. PMID: 29596070.
149. Kurt H, Bueso-Ramos CE, Khoury JD, Routbort MJ, Kanagal-Shamanna R, Patel UV, Jorgensen JL, Wang SA, Ravandi F, DiNardo C, Luthra R, Medeiros LJ, Patel KP. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol 42(5):569-577, 2018. PMID: 29635257.
150. Kurt H, Jorgensen JL, Amin HM, Patel KP, Wang SA, Lin P, Kanagal-Shamanna R, Loghavi S, Thakral B, Khogeer HA, Jabbour EJ, Li S, Yin CC, Medeiros LJ, Khoury JD. Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol 100(5):444-454, 2018. e-Pub 2018. PMID: 29385279.
151. Wang W; Kanagal-Shamanna R; Medeiros LJ. Lymphoproliferative disorders with concurrent HHV8 and EBV infection: beyond primary effusion lymphoma and germinotropic lymphoproliferative disorder. Histopatholoy 72(5):855-861, 2018. PMID: None.
152. Wang W, Kanagal-Shamanna R, Medeiros LJ. Lymphoproliferative disorders with concurrent HHV8 and EBV infection: beyond primary effusion lymphoma and germinotropic lymphoproliferative disorder. Histopathology 72(5):855-861, 2018. e-Pub 2018. PMID: 29105119.
153. Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamanna R, Wang SA, Jorgensen JL, Medeiros LJ, Ok CY. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget 9(9):8441-8449, 2018. e-Pub 2018. PMID: 29492206.
154. Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol 180(1):33-40, 2018. e-Pub 2017. PMID: 29164608.
155. Montes-Moreno S, Routbort MJ, Lohman EJ, Barkoh BA, Kanagal-Shamanna R, Bueso-Ramos CE, Singh RR, Medeiros LJ, Luthra R, Patel KP. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoS One 13(9):e0204218, 2018. e-Pub 2018. PMID: 30222780.
156. Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica 102(12):e514-e517, 2017. e-Pub 2017. PMID: 28860345.
157. Jain P, Kanagal-Shamanna R, Wierda W, Ferrajoli A, Keating M, Jain N. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. Hematol Oncol Stem Cell Ther 10:151-154, 2017. e-Pub 2016. PMID: 27352257.
158. Hu, ZH, Sun, Y, Wang, W, Medeiros, LJ, Kanagal-Shamanna, R. Refractory hairy cell leukemia-variant. Am J Hematol 92(12):1398-1399, 2017. PMID: 27727469.
159. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123(22):4391-4402, 2017. e-Pub 2017. PMID: 28743165.
160. Jain, Kantarjian P, Jain H, Short N, Yin N, Kanagal-Shamanna C, Khoury R, Konopleva J, Sasaki M, Kadia K, Garris T, Pierce R, Estrov S, Wierda Z, Cortes W, O'Brien J, Ravandi S, Jabbour F, E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol 92(10):E595-E597, 2017. PMID: 28646517.
161. Kanagal-Shamanna, Loghavi R, DiNardo S, Medeiros C, Garcia-Manero L, Jabbour G, E : Routbort E, MJ Luthra MJ, Bueso-Ramos R, Khoury C, JD. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102(10):1661-1670, 2017. e-Pub 2017. PMID: 28659335.
162. Kanagal-Shamanna, Jain R, Takahashi P, Short K, Tang N, Issa G, Ravandi G, Garcia-Manero F, Yin G, Luthra C, Patel R, Khoury K, Montalban-Bravo J, Sasaki G, Kadia K, Borthakur T, Konopleva G, Jain M, Garris N, Pierce R, Wierda S, Estrov W, Cortes Z, J ; O'Brien J, Kantarjian S, Jabbour H, E. TP53 Mutation Does Not Confer a Poor Outcome in Adult Patients With Acute Lymphoblastic Leukemia Who Are Treated With Frontline Hyper-CVAD-Based Regimens. Cancer 123(19):3717-3724, 2017. PMID: 28608976.
163. Wang, Routbort W, Ok M, Patel C, Sun K, Kanagal-Shamanna Y, Medeiros R, Wang L, SA. Characterization of TP53 mutations in clonal cytopenia of undetermined significance. Am J Hematol 92(8):E175-E177, 2017. PMID: 28494520.
164. Kanagal-Shamanna, Lopez R, Milton J, Kim D, Zhao H, Zuo C, Martinez Z, Stingo M, Lee F, Luthra J, Jabbour R, Garcia-Manero E, Medeiros G, Bueso-Ramos L, CE. Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. Am J Hematol 92(8):E168-E171, 2017. PMID: 28456995.
165. Hidalgo-López JE, Kanagal-shamanna R, Quesada AE, Thakral B, Hu Z, Mitsuhashi T, Yabe M, Garcia-Manero G, Bueso-Ramos CE. Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints. Clin Lymphoma Myeloma Leuk 17S(S16-S25), 2017. PMID: 28760297.
166. Quesada, Kanagal-Shamanna A, R. Targeted therapy-induced differentiation of acute myeloid leukemia blasts. Blood 129(26):3503-3503, 2017. PMID: 28663225.
167. Hidalgo-Lopez, Kanagal-Shamanna J, Medeiros R, Estrov L, Yin Z, Verstovsek C, Konoplev S, Jorgensen S, Mohammad J, Miranda M, Zhao R, Lee C, Zuo J, Bueso-Ramos Z, CE. Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation. Journal of the National Comprehensive Cancer Network 15(6):790-796, 2017. PMID: 28596259.
168. Jain, Prieto P, Manning V, Fowler J, Medeiros N, Kanagal-Shamanna L, R. Synchronous presentation of intra-nodal follicular dendritic cell sarcoma and Castleman disease. Am J Hematol 92(5):478-479, 2017. PMID: 27862216.
169. Boddu, Yin P, Kanagal-Shamanna C, Tang R, Thakral G, Kadia B, Konopleva T, Jabbour M, Jain E, N. An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma. Case Reports in Hematology(Article #-2413587), 2017. PMID: None.
170. Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien S, Cortes J. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). Am J Hematol 92(1):E3-E4, 2017. e-Pub 2016. PMID: 27727470.
171. Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol 91(11):E478-E479, 2016. e-Pub 2016. PMID: 27468087.
172. Jain, P, Kanagal-Shamanna, R, Wierda, W, Keating, M, Sarwari, N, Rozovski, U, Thompson, P, Burger, J, Kantarjian, H, Patel, KP, Medeiros, LJ, Luthra, R, Estrov, Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol 91(11):E478-E480, 2016. PMID: 27468087.
173. Quesada, AE, Kanagal-Shamanna, R. Metastatic rhabdomyosarcoma initially diagnosed on the bone marrow. Blood 128(17):2189-2189, 2016. PMID: 27789439.
174. Huang, LS, Wang, SA, Konoplev, S, Bueso-Ramos, CE, Thakral, B, Miranda, RN, Jabbour, E, Medeiros, LJ, Kanagal-Shamanna, R. Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report. Medicine 95(41):Article # e4934, 2016. PMID: 27741105.
175. Yin, CC, Peng, J, Li, Y, Kanagal-Shamanna, R, Muzzafar, T, DiNardo, C, Khoury, JD, Li, SY, Medeiros, LJ, Wang, SA, Tang, GL. Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies (vol 28, pg 1014, 2015). Mod Path 29(8):939-939, 2016. PMID: 27469452.
176. Zhou Y, Kanagal-Shamanna R, Zuo Z, Tang G, Medeiros LJ, Bueso-Ramos CE. Advances in B-Lymphoblastic Leukemia: Cytogenetic and Genomic Lesions. Annals of Diagnostic Pathology 23:43-50, 2016. e-Pub 2016. PMID: 27130145.
177. Hoehn D, Cortes JE, Medeiros LJ, Jabbour EJ, Hidalgo JE, Kanagal-Shamanna R, Bueso-Ramos CE. Multiparameter Analysis of the "Off-Target Effects" of Dasatinib on Bone Homeostasis in Patients with Newly Diagnosed Chronic Myelogenous Leukemia. Clinical Lymphoma, Myeloma & Leukemia 16(S1):S86-92, 2016. PMID: 27521332.
178. Ballester LY, Loghavi S, Kanagal-Shamanna R, Barkoh BA, Lin P, Medeiros LJ, Luthra R, Patel KP. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk 16(7):395-403.e1, 2016. e-Pub 2016. PMID: 27268124.
179. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer, 2016. e-Pub 2016. PMID: 27463065.
180. Vitale C, Jabbour E, Lu X, Yabe M, Shamanna RK, Daver N, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol 91(4):E274-6, 2016. e-Pub 2016. PMID: 26798971.
181. Yabe M, Medeiros LJ, Tang G, Wang SA, P Patel K, Routbort M, Bhagat G, Bueso-Ramos CE, Jorgensen JL, Luthra R, Chen W, Muzzafar T, Kanagal-Shamanna R, Khoury JD, Daneshbod Y, Davanlou M, Li S, Young KH, Miranda RN. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. Hum Pathol 50:109-117, 2016. e-Pub 2015. PMID: 26997444.
182. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Shamanna RK, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127(10):1269-75, 2016. e-Pub 2016. PMID: 26729897.
183. Jain P, Guilin T, Konoplev SN, Kanagal-Shamanna R, Wang S, Pemmaraju N, Daver N, Estrov Z. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. Am J of Hematol 91(3):354-355, 2016. PMID: 26437693.
184. Kanagal-Shamanna R, Xu-Monette ZY, Miranda RN, Dogan A, Zou D, Luthra R, Weber D, O'Malley DP, Jorgensen JL, Khoury JD, Bueso-Ramos CE, Orlowski RZ, Medeiros JL, Young KH. Crystal-Storing Histiocytosis: A Clinicopathologic Study of 13 Cases. Histopathology 68(4):482-491, 2016. PMID: 26118455.
185. Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Ok CY, Salim AA, Routbort MJ, Mehrotra M, Verstovsek S, Medeiros LJ, Luthra R. Myeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic features. Am J Clin Path 145(3):418-427, 2016. PMID: 27124925.
186. Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7(12):14251-14258, 2016. e-Pub 2016. PMID: 26883102.
187. Thakral B, Kanagal-Shamanna R. Systemic AL Amyloidosis associated with Waldenstrom Macroglobulinemia: An unusual presenting complication. Blood 127(1):1681, 2016. PMID: 27127826.
188. Kanagal-Shamanna R. Emulsion PCR: Techniques and Applications. Methods Mol Biol 1392:33-42, 2016. PMID: 26843044.
189. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol 34(2):160-168, 2016. e-Pub 2015. PMID: 26628470.
190. Ballester LY, Luthra R, Kanagal-Shamanna R, Singh RR. Advances in clinical next-generation sequencing: target enrichment and sequencing technologies. Expert Rev Mol Diagn 16(3):357-72, 2016. e-Pub 2016. PMID: 26680590.
191. Bueso-Ramos CE, Kanagal-Shamanna R, Routbort MJ, Hanson CA. Therapy-Related Myeloid Neoplasms. Am J Clin Pathol 144(2):207-218, 2015. PMID: 26185306.
192. Yin CC, Peng J, Li Y, Shamanna RK, Muzzafar T, DiNardo C, Khoury JD, Li SY, Medeiros LJ, Wang SA, Tang GL. Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. Modern Pathology 28(8):1014-1022, 2015. PMID: 26044451.
193. Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125(21):3360-3363, 2015. PMID: 25999449.
194. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SA. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res 39(3):348-354, 2015. e-Pub 2014. PMID: 25573287.
195. Challagundla P, Medeiros LJ, Kanagal-Shamanna R, Miranda RN, Jorgensen JL. Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging. Am J Clin Pathol 142(6):837-44, 2014. PMID: 25389338.
196. Adrada BE, Miranda RN, Rauch GM, Arribas E, Kanagal-Shamanna R, Clemens MW, Fanale M, Haideri N, Mustafa E, Larrinaga J, Reisman NR, Jaso J, You MJ, Young KH, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat 147(1):1-14, 2014. e-Pub 2014. PMID: 25073777.
197. Challagundla P, Jorgensen JL, Kanagal-Shamanna R, Gurevich I, Pierson DM, Ferrajoli A, Reyes SR, Medeiros LJ, Miranda RN. Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms. Arch Pathol Lab Med 138(7):903-909, 2014. PMID: 24978916.
198. Dantey K, Kanagal-Shamanna R, Zenali MJ, Quesada AE, Quintas-Cardama A, Nguyen N. Post-Transplant Lymphoproliferative Disorder of the Pancreas, Report of a Case Localized to the Pancreatic Head. Ann Clin Pathol 2(2):1020, 2014. PMID: None.
199. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123(17):2645-51, 2014. e-Pub 2014. PMID: 24627528.
200. Portier BP, Kanagal-Shamanna R, Luthra R, Singh R, Routbort MJ, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, Aldape K, Patel KP. Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol 141(4):559-72, 2014. PMID: 24619758.
201. Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, Barkoh BA, Kanagal-Shamanna R, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Singh RR. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica 99(3):465-73, 2014. e-Pub 2013. PMID: 24142997.
202. Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, Rahimi H, Reddy NG, Barkoh BA, Mishra BM, Paladugu AV, Manekia JH, Kalhor N, Chowdhuri SR, Staerkel GA, Medeiros LJ, Luthra R, Patel KP. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol 27(2):314-27, 2014. e-Pub 2013. PMID: 23907151.
203. Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP, Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol 32(2):114-20, 2014. e-Pub 2013. PMID: 24323027.
204. Kwon M, Shah S, Kanagal-Shamanna R, Young KH. A case of progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome. American Journal of Neuroradiology, Case of the Week, 2013. PMID: None.
205. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KD, Luthra R. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 15(5):607-22, 2013. e-Pub 2013. PMID: 23810757.
206. Loo EY, Medeiros LJ, Aladily TN, Hoehn D, Kanagal-Shamanna R, Young KH, Lin P, Bueso-Ramos CE, Manning JT, Patel K, Thomazy V, Brynes RK, Goswami M, Fayad LE, Miranda RN. Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. Am J Surg Pathol 37(8):1290-7, 2013. PMID: 23774171.
207. Kanagal-Shamanna R, Lehman NL, O'Donnell JP, Lim MS, Schultz DS, Chitale DA, Bueso-Ramos CE, Medeiros LJ, Inamdar KV. Differential expression of aurora-A kinase in T-cell lymphomas. Mod Pathol 26(5):640-7, 2013. e-Pub 2013. PMID: 23411487.
208. Kanagal-Shamanna R, Bueso-Ramos CE, Chen SS, Abruzzo LV, de Lima MJ, Sargent RL, Medeiros LJ, Lu G. Donor-derived isolated del(20q) after hematopoietic stem cell transplantation: report of two cases and review of the literature. J Hematopathol 6(1):25-32, 2013. PMID: None.
209. Kanagal-Shamanna R, Yin CC, Miranda RN, Bueso-Ramos CE, Wang XI, Muddasani R, Medeiros LJ, Lu G. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q). Cancer Genet 206(1-2):42-6, 2013. e-Pub 2013. PMID: 23357231.
210. Hoehn D, Miranda RN, Kanagal-Shamanna R, Lin P, Medeiros LJ. Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation. Hum Pathol 43(11):1828-38, 2012. e-Pub 2012. PMID: 22520947.
211. Kanagal-Shamanna R, Medeiros LJ, Lu G, Wang SA, Manning JT, Lin P, Penn GM, Young KH, You MJ, Vega F, Bassett R, Miranda RN. High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology 61(5):945-54, 2012. e-Pub 2012. PMID: 22804688.
212. Kanagal-Shamanna R, Zhao W, Vadhan-Raj S, Nguyen MH, Fernandez MH, Medeiros LJ, Bueso-Ramos CE. Over-expression of CYP2E1 mRNA and protein: implications of xenobiotic induced damage in patients with de novo acute myeloid leukemia with inv(16)(p13.1q22); CBFβ-MYH11. Int J Environ Res Public Health 9(8):2788-800, 2012. e-Pub 2012. PMID: 23066397.
213. Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CC. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer 118(11):2879-88, 2012. e-Pub 2011. PMID: 22038701.
214. Kondratov RV, Shamanna RK, Kondratova AA, Gorbacheva VY, Antoch MP. Dual role of the CLOCK/BMAL1 circadian complex in transcriptional regulation. FASEB J 20(3):530-532, 2006. PMID: 16507766.

Invited Articles

1. Jain, Aoki P, Keating E, Wierda M, O'Brien W, Gonzalez S, Ferrajoli G, Jain A, Thompson N, Jabbour P, Kanagal-Shamanna E, Pierce R, Alousi S, Hosing A, Khouri C, Estrov I, Cortes Z, Kantarjian J, Ravandi H, Kadia F, TM. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Annals of Oncology 28(7):1554-1559, 2017. PMID: 28379307.

Other Articles

1. Reinig EF, Rubinstein JD, Patil AT, Schussman AL, Horner VL, Kanagal-Shamanna R, Churpek JE, Matson DR Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis. Leukemia 37(8):1589-1599, 2023. PMID: 37393344.
2. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. PMID: 35732831.
3. Quesada AE, Luthra R, Jabbour E, Patel KP, Khoury JD, Tang Z, Alvarez H, Mallampati S, Garcia-Manero G, Montalban-Bravo G, Medeiros LJ, Kanagal-Shamanna R Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Cold Spring Harb Mol Case Stud 7(3), 2021. PMID: 34117074.
4. Kanagal-Shamanna R The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition. Curr Hematol Malig Rep None(None):None. PMID: 34028637.
5. El Achi H, Kanagal-Shamanna R Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies. Front Oncol 11:748250, 2021. PMID: 34660311.
6. Zarka J, Short NJ, Kanagal-Shamanna R, Issa GC Nucleophosmin 1 Mutations in Acute Myeloid Leukemia. Genes (Basel) 11(6), 2020. PMID: 32545659.
7. Ronaghy A, Yang RK, Khoury JD, Kanagal-Shamanna R Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. Curr Hematol Malig Rep None(None):None. PMID: 32382988.
8. Akkari YMN, Bruyere H, Hagelstrom RT, Kanagal-Shamanna R, Liu J, Luo M, Mikhail FM, Pitel BA, Raca G, Shago M, Shao L, Smith LR, Smolarek TA, Yenamandra A, Baughn LB Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genet 243:52-72, 2020. PMID: 32302940.
9. Burgos S, Montalban-Bravo G, Fuente L, Jabbour EJ, Kanagal-Shamanna R, Soltysiak KA, Garcia-Manero G, Mela-Osorio MJ Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report. Medicine (Baltimore) 98(1):e14011, 2019. PMID: 30608448.
10. Kanagal-Shamanna R, Hodge JC, Tucker T, Shetty S, Yenamandra A, Dixon-McIver A, Bryke C, Huxley E, Lennon PA, Raca G, Xu X, Jeffries S, Quintero-Rivera F, Greipp PT, Slovak ML, Iqbal MA, Fang M Assessing Copy Number Aberrations and Copy Neutral Loss of Heterozygosity Across the Genome as Best Practice: An Evidence Based Review of Clinical Utility from the Cancer Genomics Consortium (CGC) Working Group for Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative and Myeloproliferative Neoplasms. Cancer Genet 228-229:197-217, 2018. PMID: 30377088.
11. Xu X, Bryke C, Sukhanova M, Huxley E, Dash DP, Dixon-Mciver A, Fang M, Griepp PT, Hodge JC, Iqbal A, Jeffries S, Kanagal-Shamanna R, Quintero-Rivera F, Shetty S, Slovak ML, Yenamandra A, Lennon PA, Raca G Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genet 228-229:218-235, 2018. PMID: 30344013.
12. DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer 124(13):2704-2713, 2018. PMID: 29682723.
13. Kanagal-Shamanna R, Singh RR, Routbort MJ, Patel KP, Medeiros LJ, Luthra R Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Rev Mol Diagn 16(4):461-472, 2016. PMID: 26765348.
14. Li S, Lin P, Young KH, Kanagal-Shamanna R, Yin CC, Medeiros LJ MYC/BCL2 double-hit high-grade B-cell lymphoma. Adv Anat Pathol 20(5):315-26, 2013. PMID: 23939148.
15. Al-Ibraheemi A, Kanagal-Shamanna R, Patel KP, Konoplev SN, Mehta P, Medeiros LJ, Miranda RN Phenotypic evolution in a case of peripheral T-cell lymphoma suggests the presence of tumor heterogeneity. J Cutan Pathol 40(6):573-9, 2013. PMID: 23495765.
16. Kanagal Shamanna, R, Bueso-Ramos, CE, Chen, SS, Abruzzo, L, De Lima, M, Sargent, RL, Medeiros, LJ, Lu, G Donor-derived isolated del(20q) after hematopoietic stem cell transplantation. Journal of Hematopathology 6(1):25-32, 2013. PMID: None.
17. Hoeller S, Zhou Y, Kanagal-Shamanna R, Xu-Monette ZY, Hoehn D, Bihl M, Swerdlow SH, Rosenwald A, Ott G, Said J, Dunphy CH, Bueso-Ramos CE, Lin P, Wang M, Miranda RN, Tzankov A, Medeiros LJ, Young KH Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol 44(1):110-21, 2013. PMID: 22944294.

Editorials

1. Kanagal Shamanna, R. Never too old to blame it on your (inherited) genes. Blood 140(24):2521-2523, 2022. PMID: 36520477.

Abstracts

1. Kanagal-Shamanna R, Painter D, Churpek J, Van Marrewijk C, Fontenay M, Haase D, Haferlach C, Van De Loosdrecht A, Jansen J, Malcovati L, Hellstrom-Lindberg E, Hasserjian R. AUTOMATED DIGITAL TOOL FOR MDS AND MDS/MPN CLASSIFICATION USING WHO AND ICC: INTERNATIONAL GUIDELINES WORKING GROUP ON MDS DIAGNOSIS, PROGNOSIS, AND GERMLINE PREDISPOSITION. Leukemia Research 128(Supplement S):None, 2023. PMID: None.
2. Evans M, Khoury J, DiNardo C, Garcia-Manero G, Yang H, Loghavi S, Montalban-Bravo G, Patel K, Quesada A, Konoplev S, Garces S, Toruner G, Bueso-Ramos C, Medeiros LJ, Kanagal-Shamanna R. Bone Marrow Pathologic Abnormalities in Myelodysplastic Syndrome (MDS) Patients with Underlying TERT/TERC Germline Alterations. USCAP ANNUAL MEETING 2022 102(Supplement 1):945-946, 2022. PMID: None.
3. Cantu M, Kanagal-Shamanna R, Bueso-Ramos C, Patel S, Geyer J, Tam W, Li P, George T, Nichols M, Rogers H, Liu YC, Aggarwal N, Kurzer J, Maracaja D, Hsi E, Zaiem F, Babu D, Fourcar K, Laczko D, Bagg A, Orazi A, Arber D, Hasserjian R, Weinberg O. Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-related and De Novo Acute Myeloid Leukemia: A Multi-institutional Study by the Bone Marrow Pathology Group. USCAP Annual Meeting 2022 102(Supplement 1), 2022. PMID: None.
4. Qiu LQ, Garcia-Manero G, Montalban-Bravo G, Yang H, Tang ZY, Patel K, Loghavi S, Ok CY, Bueso-Ramos C, Medeiros LJ, Kanagal-Shamanna R. Somatic U2AF1 Mutations Involving Codons Q157 and S34 are Associated with Distinct Clinical and Molecular Characteristics but Similar Outcomes in Patients with Myelodysplastic Syndrome. USCAP ANNUAL MEETING 2022 102(Supplement 1):1004-1005, 2022. PMID: None.
5. Wang XQ, Fang H, Kanagal-Shamanna R, Tang GL, Wang W, Xu J, Jabbour E, Jain N, Jorgensen J, Medeiros LJ, Wang S, Konoplev S. CD10-/CD15+/CD34-Immunophenotype Does Not Predict KMT2A Rearrangement in Adults with B-Lymphoblastic Leukemia/Lymphoma (B-LBL). USCAP ANNUAL MEETING 2022 102(Supplement 1):1034-1034, 2022. PMID: None.
6. Kim DH, Li SY, Kanagal-Shamanna R, Miranda R, Vega F, Medeiros LJ, Ok CY. Next-generation Sequencing Revealed Frequent TP53 mutation in Mantle Cell Lymphoma with Enhancer of Zeste Homolog 2 (EZH2) Expression. USCAP ANNUAL MEETING 2022 102(Supplement 1):966-967, 2022. PMID: None.
7. Levy B, Baughn L, Chartrand S, LaBarge B, Claxton D, Lennon P, Akkari Y, Cujar C, k Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang LJ, Fang M, Kanagal-Shamanna R, Broach J. Optical genome mapping for assessment of genomic aberrations in acute myeloid leukemia: a multicenter evaluation. ACMG 2021 Annual Clinical Genetics Meeting 132(Supplement 1):S218-S218, 2021. PMID: None.
8. Tashakori M, Wang W, Wang S, Kanagal-Shamanna R, Loghavi S, Medeiros LJ, Tapan K, Daver N, Ravandi-Kashani F, Khoury J. De Novo and Therapy-Related Pure Erythroid Leukemia Harbor Distinct TP53 Genetic Alterations. Laboratory Investigation-2021 Annual USCAP 101(Supplement 1):898-900, 2021. PMID: None.
9. Shuai W, Chen W, Floyd K, Routbort M, San Lucas F, Kanagal-Shamanna R, Zuo Z, Loghavi S, Ok CY, Yin CC, Luthra R, Medeiros LJ, Patel K. Ultra-Rapid Reporting of TP53 Mutation in Myeloid Neoplasms by Using Next Generation Sequencing. Laboratory Investigation-2021 Annual USCAP 101(Supplement 1):891-892, 2021. PMID: None.
10. de Cap MR, Wu L, Pihan G, Patel S, Tam W, Bueso-Ramos C, Kanagal-Shamanna R, Raess P, Siddon A, Narayanan D, Morgan E, Pinkus G, Mason E, Hsi E, Rogers H, Toth L, Foucar K, Hurwitz S, Bagg A, Rets A, George T, Orazi A, Arber D, Hasserjian R, Weinberg O. Clinical and Genomic Findings of Myeloid Sarcoma with an Emphasis on NPM1 Mutations: A study from the Bone Marrow Pathology Group. Laboratory Investigation-2021 Annual USCAP 101(Supplement 1):884-885, 2021. PMID: None.
11. Hussein S, DiNardo C, Khoury J, Fang H, Lyapichev K, Garces S, Kanagal-Shamanna R, Ok CY, Patel K, Routbort M, Medeiros LJ, Wang S, Loghavi S. Emerging WT1mut Clones Contribute to Relapse in NPM1mut AML Patients. Laboratory Investigation-2021 Annual USCAP 101(Supplement 1):818-819, 2021. PMID: None.
12. Kanagal-Shamanna R, Evans A, Bueso-Ramos C, Garcia-Manero G, Medeiros LJ, Iqbal MA. Comprehensive Genomic Assessment using both NGS and CGH-SNP Analysis is Essential to Identify Clonal Abnormalities in Idiopathic Cytopenia(s) of Undetermined Significance. Laboratory Investigation-2021 Annual USCAP 101(Supplement 1):857-857, 2021. PMID: None.
13. Nezami B, Toruner G, Routbort M, San Lucas F, Yang R, Seyedjafari R, Chen H, Rashid A, Loghavi S, Roy-Chowdhuri S. Clinical Utility of NGS-Based Gene Fusion Testing in Solid Tumors. Laboratory Investigation-2021 Annual USCAP 101(Supplement 1):513-514, 2021. PMID: None.
14. Kadia TM, Borthakur G, Pemmaraju N, Daver N, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Bravo GM, Short NJ, Jain N, Ferrajoli A, Bhalla K, Jabbour E, Kanagal-Shamanna R, Takahashi K, Malla R, Marek K, Brandt M, Popat UR, Andreeff M, Cortes JE, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
15. Strati P, Samaniego F, Gallardo M, Noorani M, Hagemeister FBB, Westin JR, Lee HJ, Rodriguez MA, Neelaup SS, Gunther JR, Kanagal-Shamanna R, Vega F, Fowler NH, Flowers CR, Nastoupil LJ. Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
16. Bravo GM, Kanagal-Shamanna R, Darbaniyan F, Ganan-Gomez I, Sasaki K, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien KS, Bueso-Ramos CE, Kantarjian HM, Garcia-Manero G. Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
17. DiNardo CD, Konopleva M, Borthakur G, Perez JMR, Guerra VA, Kanagal-Shamanna R, Paul S, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov ZE, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
18. Kanagal-Shamanna R, Montalban Bravo G, Katsonis P, Sasaki K, Class C, Benton CB, Jabbour E, Chien KS, Luthra R, Bueso-Ramos CE, Kadia TM, Andreef M, Short NJ, Daver N, Routbort M, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, K-A D, Soltysiak KA, Lichtarge O, Medeiros JJ, Kantarjian HM, Garcia-Manero G. Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
19. Wang M, Jain P, Yao Y, Liu Y, Zhao S, Hill H, Moghrabi O, Lee HJ, Samaniego F, Westin J, Nastoupil LJ, Kanagal-Shamanna R, Ok CY, Chen W, Oriabure O, Che Y, Li Y, Feng L, Gonzalez GMN, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Vega F, Yin CC, Avellaneda M, Badillo M, Flowers C, Wang L. Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-1 Clinical Trial. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
20. Alwash Y, Kanagal-Shamanna R, Cuerra VA, Daver N, Konopleva M, Ravandi F, Kadia TM, DiNardo CD, Issa GC, Borthakur G, Loghavi S, Takahashi K, Yilmaz M, Maiti A, Kantarjian HM, Kornblau SM, Short NJ. Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
21. Kanagal-Shamanna R, Kantarjian HM, Khoury JD, Takahashi K, Montalban-Bravo G, Short NJ, Yin CC, Patel K, Loghavi S, Ravandi F, Konopleva M, Jain N, Garcia-Manero G, Daver N, Kadia TM, DiNardo CD, O'Brien SM, Lughra R, Ei J. Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
22. Jain P, Kanagal-Shamanna R, Navsaria L, Ok CY, Hill H, Jung D, Gonzalez GMN, Lee HJ, Nair R, Ahmed S, Steiner RE, Tang G, Li S, Patel K, Thirumurth S, Tinsu P, Xu G, Vega F, Flowers C, Wang M. Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
23. Loghavi S, DiNardo CD, Takahashi K, Kanagal-Shamanna R, Tanaka T, Furudate K, Short NJ, Kadia TM, Konopleva M, Farnoud N, Pierce SA, Khoury JD, Jorgensen JL, Patel KP, Medeiros LJ, Kantarjian HM, Ravandi F, Wang SA. Clonal Hematopoiesis and Its Implications for Flow Cytometric Assessment of Measurable Residual Disease in Patients with NPM1-mutated Acute Myeloid Leukemia. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
24. Sasaki K, Jabbour E, Montalban Bravo G, Short NJ, Kanagal-Shamanna R, Kadia TM, Borthakur G, Pemmaraju N, Cortes JE, Ravandi F, Alvarado Y, Chien KS, Yang H, Kantarjian HM, Garcia-Manero G. Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
25. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz M, Kanagal-Shamanna R, Patel K, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver, Jabbour E, Yilmaz M, Issa GC, Andreeff M, Kadia TM. Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
26. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE Sasaki K, Fowler NH, Kadia TM, Konopleva M, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen JL Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
27. Jain P, Yao Y, Zhao S, Liu Y, Hill H, Che Y, Li Y, Jordan AA, Mcintosh J, Lee HJ, Steiner RE, Samaniego F, Westin J, Nastoupil LJ, Nair R, Ahmed S, Ok CY, Kanagal-Shamanna R, Oriabure O, Xu G, Chen W, Moghrabi O, McClain CM, Badillo M, Thirumurthi S, Santos D, Iliescu C, Yin CC, Li S, Tang G, Vega F, Neelapu SS, Flowers C, Wang L, Wang M. Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
28. Darbaniyan F, Bravo GM, Wei Y, Kanagal-Shamanna R, Sasaki K, Yang H, Soltysiak KA, Chien KS, K-A D, Garcia-Manero G. Impact of Hemoglobin Level As a Continuous Variable in Calculating Prognosis in MDS: Incorporation into LSC4 and IPSS-R. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
29. Alotaibi AS, Yilmas M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Wang SA, Tang G, Guerra VA, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Pater KP, Takahashi K, Andreeff M, Cortes JE, Konopleva M, Ravandi F, Kantarjian HM, Daver N. Patterns of Secondary Resistance Differ in Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Type I Versus Type II FLT3-Inhibitors (FLT3i’s). 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
30. Bravo GM, Kanagal-Shamanna R, Guerra V, Perez JMR, Hammond D, Paul S, Naqvi K, Sasaki K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov ZE, Khoury JD, Loghavi S, Pierce SA, Bueso-Ramos CE Patel K, Kantarjian HM, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
31. Bravo GM, Darbaniyan F, Kanagal-Shamanna R, Ganan-Gomez I, Sasaki K, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien KS, Bueso-Ramos CE, Kantarjian HM, Garcia-Manero G. Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
32. Tang G, Yin CC, Ok CY, Navsaria L, Badillo M, Chen W, Li Y, Che Y, Liu Y, Oriabure O, Nogueras GM, Westin J, Nastoupil LJ, Ahmed S, Nair R, Thirumurthi S, Li S, Kanagal-Shamanna R, Vega F, Flowers C, Wang M. Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors – Comprehensive Analysis of 396 Patients. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
33. Yilmaz M, Alfaye M, Kadia TM, DiNardo C, Borthakur G, Loghavi S, Konopleva M, Kanagal-Shamanna R, Patel K, Jabbour E, Garcia-Manero G, Pemmaraju N, Pierce SA, Issa GC, Short NJ, Bravo GM, Takahashi K, Assi R, Alotaibl AS, Andreeff M, Cortges JE, Kantarjia HM, Ravandi F, Daver N. Outcomes with Sequential FLT3-Inhibitor (FLT3i) Based Therapies in Patients (pts) with FLT3-Mutated Acute Myeloid Leukemia (AML) Exposed to Prior FLT3i Based Therapies. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
34. Bravo GM, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Short NJ, Issa GC, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov ZE, Khoury JD, Loghavi S, Pierce SA, Bueso-Ramos CE, Patel K, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
35. Kanagal-Shamanna R, Bravo GM, Sasaki K, Bueso-Ramos CE, Jabbour E, Wei Y, Darbaniyan F, Routbort M, Pierce SA, Soltysiak KA, Patel K, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
36. Kanagal-Shamanna R. Optical Mapping for Detection of Genomic Abnormalities in Hematologic Malignancies. 62nd ASH Annual Meeting & Exposition, Dec. 2020 / Novel Diagnostic Genomic Tools and Technologies Session, 2020. PMID: None.
37. Kanagal-Shamanna R, Adema V, Ma F, Santoni A, Yang H, Ganan-Gomez I, Thongon N, Montalban-Bravo G, Pellegrini M, Bueso-Ramos CE, Garcia-Manero G, Colla S. SF3B1-Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
38. Rivera D, Kantarjian HM, Borthakur G, Konopleva M, Kanagal-Shamanna R, Pemmaraju N, Daver N, DiNardo CD, Takahashi K, Jabbour E, Montalban-Bravo G, Yilmaz M, Pierce SA, Andreeff M, Bhalla KN, Garcia-Manero G, Ravandi F, Tapan MK. Implications of RAS Mutational Status in Subsets of Patients with NewDiagnosed Acute Myeloid Leukemia (AML) across Therapy Groups. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
39. El Hussein S, Medeiros LJ, Lyapichev KA, Gruschkus SK, Wei P, Schlette E, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
40. Jain P, Zhang S, Kanagal-Shamanna R, Navsaria L, Ok CY, Tang G, Yin CC, Badillo M, Chen W, Oriabure O, Lee HJ, Westin J, Nastoupil LJ, Moghrabi O, Che Y, Samaniego F, Ahmed S, Nair R, Li S, Vega F, Flowers C, Wang L, Wang W. Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma. 62nd ASH Annual Meeting & Exposition, Dec. 2020, 2020. PMID: None.
41. Higgins J, Williams LN, Valentine CC, Pratt G, Kanagal-Shamanna R, Short NJ, Ueda M, Storb R, Radich JP, Salk JJ. Clonal landscapes of hematologic malignancies redefined by ultrasensitive duplex sequencing. Clin Cancer Res - AACR Special Conference on Advances in Liquid Biopsies 26(11):26-27, 2020. PMID: None.
42. Khanlari M, Loghavi S, Wang S, El Hussein S, Tashakori M, Bueso-Ramos C, Yin CC, Kanagal-Shamanna R, Khoury J, Medeiros LJ, Patel K, Popat U, Konoplev S. Importance of Bone Marrow Morphologic Features for Surveillance of Patients with Myelofibrosis Following Molecular Clearance after Stem Cell Transplant. Laboratory Investigation-109th Annual USCAP 100(Supplement 1):1322-1322, 2020. PMID: None.
43. Sukswai N, Khoury J, Patel K, Routbort M, Luthra R, Bueso-Ramos C, Loghavi S, Medeiros LJ, Kanagal-Shamanna R. Characterization of Bone Marrow Morphologic and Genetic Features of Myeloid Neoplasms with Germline DDX41 Mutation in 10 Distinct Pedigrees. Laboratory Investigation-109th Annual USCAP 100(Supplement 1):1394-1394, 2020. PMID: None.
44. Kanagal-Shamanna R, Orazi A, Hasserjian R, Arber D, Reichard K, Hsi E, Bagg A, Rogers H, Geyer J, Devins K, Pozdnyakova O, George T, Dal Cin P, Wang S, Bueso-Ramos C. Myeloid Neoplasms with Isolated Isochromosome 17q Represent a Distinct Subset within Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable (MDS/MPN-U) with a Significantly Worse Outcome: A Multi-Institutional Collaborative Study from the Bone Marrow Pathology Group. Laboratory Investigation-109th Annual USCAP 100(Supplement 1):1317-1318, 2020. PMID: None.
45. Tashakori M, Khoury J, Routbort M, Patel K, Wang S, Ok CY, Kanagal-Shamanna R, Luthra R, Hu SM, Khanlari M, El Hussein S, Lin P, Bueso-Ramos C, Medeiros LJ, Loghavi S. Exploring the Molecular Grey Zone of Myeloid Neoplasms: Concurrent SRSF2 and Classic MPN Driver Mutations. Laboratory Investigation-109th Annual USCAP 100(Supplement 1):1395-1396, 2020. PMID: None.
46. Short N, Kantarjian H, Sasaki K, Kanagal-Shamanna R, Ravandi FR, Cortes J, Konopleva M, Issa G, Kornblau S, Garcia-Manero G, Rivera V, Garris R, Salk J, Prichard J, Radich J, Jabbour E. Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Cliinical Lymphoma Myeloma & Leukemia - 2019 ASCP 19(Supplement 1):S186-S186, 2019. PMID: None.
47. Chien ZK, Class C, Bravo GM, Sasaki K, Naqvi K, Gomez IG, Wei Y, Yang H, Kanagal-Shamanna R, Soltysiak K, Kantarjian H, Garcia-Manero G. LILRB4 Expression in CMML and MDS Based on Response to Hypomethylating Agents. Cliinical Lymphoma Myeloma & Leukemia - 2019 ASCP 19(Supplement 1):S341-S341, 2019. PMID: None.
48. Molica M, Dinardo CD, Patel KP, Keating MJ, Wierda WG, Thompson PA, Jain N, Takahashi K, Kanagal-Shamanna R, Routbort M, Tang GI, Tang ZY, Ferrajoli A. Occurrence of other cancers in patients with chronic lymphocytic leukemia and mutations in protection of telomeres 1 (POT1) gene. Journal of Clinical Pathology-ASCO Annual Meeting 2019 37(15):Supplement, 2019. PMID: None.
49. Chien KS, Benton CB, Class CA, Kadia TM, Dinardo CD, Konopleva M, Andreef M, Sasaki K, Naqvi K, Gomez IG, Wei Y, Yang H, Pierce SA, Patel KP, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Moltalban-Bravo G. Patterns of leukemic transformation in patients with TP53-mutant myelodysplastic syndromes. Journal of Clinical Pathology-ASCO Annual Meeting 37(15):Supplement, 2019. PMID: None.
50. Ok CY, Chen ZN, Loghavi S, Kanagal-Shamanna R, Zuo Z, Yin CC, Routbort M, Patel K, Luthra R, Medeiros LJ, Wang S. Prevalence and Clinical Implications of Splicing Factor Gene Mutation in Patients with Primary Myelofibrosis. Laboratory Investigation-108th Annual USCAP 2019 99(Supplement 1), 2019. PMID: None.
51. Bravo GM, Kanagal-Shamanna R, Benton CB, Colla S, Ganan-Gomez I, Sasaki K, Ravandi F, Kadia TM, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Naqvi K, Konopleva MY, Pierce SA, Bueso-Ramos CE, Patel K, Kantarjian HM, Garcia-Manero G. Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
52. Short NJ, Kantarjian HM, Loghavi S, Huang XL, Qiao W, Borthakur G, Kadia TM, Daver NG, Ohanian MN, DiNardo CD, Estrov ZE, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour EJ, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce SA, Cortes JE, Konopleva MY, Garcia-Manero G, Ravandi F. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
53. Lopez JH, Kanagal-Shamanna R, Saurez RR, Bueso-Ramos CE. Myeloid Blast Phase of PV Can be Differentiated from De Novo AML with JAK2 Mutation By Its Adverse Cytogenetics and Distinct Molecular Profile. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
54. Tallis E, Benton CB, Khan A, Assi R, DiNardo CD, Hornbaker MJ, Major CK, Boddu P, Kanagal-Shamanna R, Patel KP. Diverse Landscape of TET2 Variants in MDS and AML. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
55. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Ahmed M, Nava D, Badillo M, Nomie K, Patel KP, Lee HJ, Hagemeister FB, Fayad L, Nastoupil LJ, Medeiros LJ, Neelapu SS, Romaguera JE, Fowler NH, Wang L, Wang M. Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
56. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Cortes JE, Konopleva MY, Issa GC, Kanagal-Shamanna R, Kornblau SM, Garcia-Manero G, Rivera V, Garris RE, Salk J, Prichard J, Radich JP, Jabbour EJ. Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
57. Jain P, Nastoupil LJ, Kanagal-Shamanna R, Gonzalez GMN, Noorani M, Romaguera JE, Fayad L, Samaniego F, Westin JR, Medeiros LJ, Neelapu S, Wang M, Fowler NH. Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
58. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian MN, Pemmaraju N, Jabbour EJ, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Garg N, Wang XM, Sondermann K, Cruz N, Wei CJ, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda, WG. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
59. Jain P, Kanagal-Shamanna R, Zhang SJ, Ok CY, Gonzalez GMN, Ahmed M, Omarya GP, Ghorab A, Boddu PC, Chen W, Lee HJ, Badillo M, Nomie K, Fayad L, Nastoupil LJ, Champlin, RE Neelapu SS, Patel K, Medeiros LJ, Romaguera JE, Fowler NH, Wang LH, Wang M. Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
60. Barkoh BA, Kanagal-Shamanna R, Konopleva M, Medeiros L, Luthra R, Quesada AE, Patel KP. Development of a clinical CD33 genotying assay to predict response to Gemtuzumab. Journal of Molecular Diagnostics- 2018 AMP Annual Meeting 20(5):896-896, 2018. PMID: None.
61. Ahmed M, Guo H, Zhang SJ, Sehgal L, Jain P, Kanagal-Shamanna R, Ok CY, Leeming A, Yao YX, Zhang L, Nomie K, Wang LH, Wang M. Unravelling the Heterogeneity of Mantle Cell Lymphoma Ecosystem By Single Cell RNA Sequencing. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
62. Ganan-Gomez I, Alfonso A, Yang H, Santoni A, Marchica V, Fiorini E, Montalban-Bravo G, Ogoti Y, Manyam G, Jiang S, Bao N, Jackson C, Rose A, Kanagal-Shamanna R, Bueso-Ramos CE, Cambo B, Giuliani N, Crugnola M, Konopleva MY, Clise-Dwyer K, Garcia-Manero G, Colla, S. Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
63. Hornbaker MJ, Malaney P, Zhang XR, Duan RZ, Shah V, Herbrich S, Gallardo M, Jacamo R, Link T, Ma HX, Alybayev S, Kornblau SM, Hu P, Sarbassov D, Kanagal-Shamanna R, Bueso-Ramos CE, Post SM. hnRNP K Overexpression Drives Myeloid Malignancy Via Interaction with RUNX1. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
64. Montalban-Bravo G, Benton CB, Kanagal-Shamanna R, Sasaki K, Assi R, Kadia TM, Ravandi F, Ganan-Gomez I, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Pemmaraju N, Konopleva MY, Pierce SA, Bueso-Ramos CE, Kornblau SM, Patel K, Colla S, Kantarjian HM, Andreeff M, Garcia-Manero G. Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
65. Lopez JH, Kanagal-Shamanna R, Macek B, Carballo-Zarate A, Saurez RR, Reyes S, Zhao C, Bueso-Ramos CE. Splicing Factor Pathway Is Rarely Mutated in Myeloid Blast Phase of PV with Dysmyelopoiesis and Ring Sideroblasts. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
66. Kanagal-Shamanna R, Sasaki K, Bravo GM, Benton CB, Jabbour EJ, Borthakur G, Kadia TM, Bueso-Ramos CE, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G. Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
67. Garcia-Manero G, Sasaki K, Montalban-Bravo G, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva MY, Colla S, Yang H, Rausch CR, Gasior Y, Bueso-Ramos CE, Kanagal-Shamanna R, Patel KP, Kantarjian, HM. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
68. Sakhdari A, Loghavi S, Kanagal-Shamanna R, Yin C, Zuo Z, Routbort M, Patel KP, Luthra R, Medeiros JL, Ok CY. RAS and TP53, Not NOTCH1, Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with Hypercvad. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
69. Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso A, Yilmaz M, Short NJ, Assi R, Jabbour EJ, Ravandi F, Kadia TM, Pierce SA, Takahashi K, Gonzalez GMN, Kanagal-Shamanna R, Patel KP, Kantarjian HM, Garcia-Manero, G. Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
70. Jain N, Thompson PA, Burger JA, Ferrajoli A, Borthakur G, Bose P, Estrov ZE, Kadia TM, Takahashi K, Garg N, Wang XM, Kanagal-Shamanna R, Patel K, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
71. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Naqvi K, Pierola AA, Yilmaz M, Short NJ, Jabbour EJ, Ravandi F, Kadia TM, Pierce SA, Takahashi K, DiNardo CD, González GMN, Abaza Y, Devendra KC, Chamoun K, Sakurai K, Patel KP, Cortes JE, Kantarjian HM, Garcia-Manero G. The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. PMID: None.
72. Ruiz-Cordero R, Floyd K, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Luthra R, Kantarjian HM, Medeiros JL, Patel KP OK, Cy. PTPN11 mutation is uncommon in acute myeloid leukemia, but associated with a complex karyotype, co-mutations in DRAS or NRAS and poor prognosis. Journal of Molecular Diagnostics- 2018 AMP Annual Meeting 20(6):930-931, 2018. PMID: None.
73. Hu BY, Patel K, Chen HC, Wang XM, Luthra R, Routbort M, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok C, Loghavi S, Thompson, PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Wierda WG. Association of ATM mutation and unmutated IGHV status with shorter time to first treatment (TTFT): An analysis of multigene mutation profiling and standard prognostic clinical markers in 384 treatment-naive (TN) chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology-2018 ASCO Annual Meeting 36(15):Supplement S, 2018. PMID: None.
74. Ghorab A, Kantarjian HM, Jain P, Kanagal-Shamanna R, Jabbour E, Sasaki K. Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes. Journal of Clinical Oncology-2018 ASCO Annual Meeting 36(15):Supplement S, 2018. PMID: None.
75. Ruiz-Cordero, Hidalgo-Lopez R, Bueso-Ramos J, Routbort C, Kanagal-Shamanna M, Zuo R, Yin Z, Loghavi C, Ok S, Jorgensen C, Wang J, Tang S, GL ; Luthra GL, Medeiros R, Patel L, K. Distinct Genetic Features of Myelodysplastic Syndromes as Defined in the Revised 2016 World Health Organization Classification. MODERN PATHOLOGY-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):549-549, 2018. PMID: None.
76. Gowda, L ; Shah L, Badar M, Bashir I, Shah Q, Patel N, Kanagal-Shamanna I, Mehta R, Weber R, D ; Lee D, Manasanch H, Shah E, Thomas A, Parmar S, Nieto S, Orlowski Y, Champlin R, Qazilbash R, MH. Primary Plasma Cell Leukemia: Stem Cell Transplant in an Era of Novel Induction Drugs. Biology of Blood and Marrow Transplantation-Blood and Marrow Transplantation Tandem Meetings of the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR) / American-Society-for-Blood-and-Marrow-Transplantation (ASBMT) 24(3):S249-S250, 2018. PMID: None.
77. Quesada, Routbort A, Luthra M, Patel R, Hidalgo-Lopez K, Bueso-Ramos J, Medeiros C, Kanagal-Shamanna L, R. RUNX1 Mutations in Myelodysplastic Syndrome. MODERN PATHOLOGY-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):545-545, 2018. PMID: None.
78. Hidalgo-Lopez JD, Quesada AE, Gong ZM, Wang W, Kanagal-Shamanna R, Hu SM, Yin CC, Cortes J, Bassett RL, Medeiros LJ, Kantarjian HM, Bueso-Ramos C. Indications for Bone Marrow Biopsy at Time of First Assessment in Patients with Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor Therapy. Modern Pathology/USCAP 2018 31(Supplement 2):521-521, 2018. PMID: None.
79. Kanagal-Shamanna, Hidalgo-Lopez R, Patel J, Luthra K, Routbort R, Quesada M, Zhao A, Lee C, Medeiros J, Bueso-Ramos L, C. Myelodysplastic Syndrome with SRSF2/U2AF1 Mutations Shows Ring Sideroblastic Phenotype Similar To SF3B1 Mutation but has Adverse Clinicopathologic Features. MODERN PATHOLOGY-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP7 Supplement 2:526-527, 2018. PMID: None.
80. Sakhdari, Patel A, Ok K, Kanagal-Shamanna C, Yin R, Zuo C, Hu Z, Routbort S, Luthra M, Medeiros R, Khoury L, Loghavi J, S. TP53 Mutations are Common in Mantle Cell Lymphoma, Including the Indolent Leukemic Non-Nodal Variant. MODERN PATHOLOGY-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):549-549, 2018. PMID: None.
81. Chowduri SR, Mehrotra M, Bolivar A, Kanagal-Shamanna R, barkoh BA, Hannigan B, Zalles S, Ye WR, Duose D, Broaddus R, Staerkel G, Wistuba I, Medeiros LJ, Luthra R. Utilizing Discarded Supernatants for Mutation Profiling of Malignant Lung FNA Specimens: "Next Generation" Cytopathology. Modern Pathology/USCAP 2018 31(Supplement 2):170-170, 2018. PMID: None.
82. Thakral, Muzzafar B, Badar T, Wang I, Miranda S, Lin R, Khoury P, Routbort J, Kanagal-Shamanna M, Loghavi R, Ok S, Yin C, Zuo C, Verstovsek Z, Benton S, Luthra C, Bueso-Ramos R, Medeiros C, Patel L, K. Clinicopathologic and Molecular Characteristics of Myeloid Neoplasms with Non-Canonical MPL Mutations. MODERN PATHOLOGY-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):559-560, 2018. PMID: None.
83. Quesada, DiNardo A, Routbort C, Bueso-Ramos M, Kanagal-Shamanna C, Zuo R, Yin Z, Loghavi C, Ok S, Wang C, Benton S, Kantarjian C, Luthra H, Medeiros R, Patel L, K. DDX41 Mutations in Myeloid Neoplasms Are Associated with Male Predominance, TP53 mutation and a High Risk of Progression to AML. MODERN PATHOLOGY-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):545-545, 2018. PMID: None.
84. Sakhdari, Routbort A, Bueso-Ramos M, Patel C, Luthra K, Ok R, Loghavi C, Zuo S, Yin Z, Khoury C, Medeiros J, Kanagal-Shamanna L, R. Myelodysplastic Syndromes with EZH2 Mutations Frequently Show Multilineage Dysplasia, Chromosome 7 Alterations and Concomitant Mutations in ASXL1, RUNX1 and TET2. MODERN PATHOLOGY-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):549-500, 2018. PMID: None.
85. Angelova E, Luthra R, Patel K, Quesada AE, Khoury J, Zuo Z, Yin CC, Medeiros LJ, Bueso-Ramos C, Kanagal-Shamanna R. Lack of typical clinicomorphologic features associated with Acute Myeloid Leukemia with variant (Non-Type A) CBFB-MYH11 fusion transcript presents diagnostic challenges. Modern Pathology/USCAP 2018 31(Supplement 2):496-496, 2018. PMID: None.
86. Ruiz-Cordero, Chen R, Floyd W, Rodriguez K, Galbincea S, Barkoh J, Routbort B, Luthra M, Singh R, Hatfield R, Kanagal-Shamanna D, Yin R, Zuo C, Loghavi Z, Ok S, Medeiros C, Patel J, KP. Breaking the Turnaround Time Barrier in Next Generation Sequencing Based Clinical Mutation Profiling Using an Integrated Workflow and Informatics Approach. Journal of Molecular Diagnostics/Annual Meeting of the Association for Molecular Pathology (AMP) 19(6):997-998, 2017. PMID: None.
87. Kanagal-Shamanna, Luthra R, Routbort R, Singh M, Floyd R, Abraham K, Hai R, Yin S, Zuo C, Ok Z, Loghavi C, Medeiros S, Patel L, KP. Multi-Platform-Based Comprehensive Molecular Analysis of Hematological Malignancies for Somatic Mutations, Copy Number Changes and Translocations for Routine Clinical Testing. Journal of Molecular Diagnostics/Annual Meeting of the Association for Molecular Pathology (AMP) 19(6):964-964, 2017. PMID: None.
88. Luthra, R, Patel, KP, Routbort, MJ, Medeiros, L, Quesada, AE, Kanagal-Shamanna, R. Sequential NGS-Based Multi-Gene Mutational Analysis in de novo Acute Myeloid Leukemia with RUNX1 Mutation. Journal of Molecular Diagnostics/Annual Meeting of the Association for Molecular Pathology (AMP) 19(6):969-969, 2017. PMID: None.
89. Mallampati, Duose S, Zalles D, Harmon S, Kanagal-Shamanna M, Mehrotra R, Chen M, Lan W, Windham C, Wistuba J, II ; Singh II, Kopetz R, Luthra S, R. Linear Amplification Coupled Exponential (LACE) PCR: A Novel Approach to Improve the Performance of Molecular Barcoded Next-Generation Sequencing Technology. Journal of Molecular Diagnostics/Annual Meeting of the Association for Molecular Pathology (AMP) 19(6):1064-1064, 2017. PMID: None.
90. Hidalgo-Lopez, Kanagal-Shamanna J, Quesada R, Thakral A, Hu B, Mitsuhashi Z, Yabe T, Garcia-Manero M, G ; Bueso-Ramos G, CE. Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints. Clinical Lymphoma, Myeloma & Leukemia/4th Annual Meeting of the Society-of-Hematologic-Oncology (SOHO) 17(S):S16-S25, 2017. PMID: 28760297.
91. Kadia, Boddu T, Ravandi P, Garcia-Manero F, Borthakur G, Andreeff G, Jabbour M, Dinardo E, Konopleva C, Daver M, Takahashi N, Patel K, Kanagal-Shamanna K, Cortes R, Kantarjian J, HM. Outcomes with lower intensity therapy in TP53-mutated AML. Journal of Clinical Oncology 35(15-Supplement), 2017. PMID: None.
92. Kurt, H, Bueso-Ramos, CE, Khoury, J, Routbort, MJ, Kanagal-Shamanna, R, Jorgensen, JL, Wang, S, DiNardo, C, Rajyalakshmi, L, Medeiros, LJ, Patel, KP. Characterization of IDH1 p.R132H Mutant Clones Using Mutation Specific Antibody in Myeloid Neoplasms. Laboratory Investigation/106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 97(Supplement 1):358A-358A, 2017. e-Pub 2017. PMID: None.
93. Kanagal-Shamanna, R, Loghavi, S, Medeiros, LJ, Routbort, MJ, Bueso-Ramos, CE, Khoury, J. Familial Platelet Disorder with Propensity to Myeloid Malignancy (FPDMM) Associated with Germline RUNX1 Mutation Shows Characteristic Morphologic Features. Laboratory Investigation/106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 97(Supplement 1):356A-356A, 2017. e-Pub 2017. PMID: None.
94. Kurt, H, Bueso-Ramos, CE, Khoury, J, Routbort, MJ, Kanagal-Shamanna, R, Jorgensen, Jeffrey L, Wang, S, DiNardo, C, Rajyalakshmi, L, Medeiros, LJ, Patel, KP. Genetic Landscape of Non-R882 DNMT3A Mutations Is Distinct from DNMT3A R882 Mutations. Laboratory Investigation/106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 97(Supplement 1):371A-371A, 2017. PMID: None.
95. Jain, P, Kanagal-Shamanna, R, Lucas S, F, Wang, M, Romaguera, JE, Fayad, LE, Oki, Y, Westin, JR, Medeiros, J, Fowler, N. Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib). Blood/58th Annual Meeting and Exposition of the American-Society-of-Hematology 128(22), 2016. PMID: None.
96. Jain, P, Kantarjian, HM, Jabbour, EJ, Kanagal-Shamanna, R, Patel, KP, DellaSala, SE, Garcia-Manero, G, Borthakur, G, Ravandi, F, O'Brien, SM, Cortes, JE. Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase CML). Blood/58th Annual Meeting and Exposition of the American-Society-of-Hematology 128(22), 2016. PMID: None.
97. Kanagal-Shamanna, R, Jain, P, Luthra, R, Patel, KP, Garcia-Manero, G, Takahashi, K, Ravandi, F, Sasaki, K, Kadia, TM, Borthakur, G, Konopleva, M, Jain, N, Garris, R, Pierce, S, Estrov, Z, Wierda, WG, O'Brien, SM, Cortes, JE, Kantarjian, HM, Jabbour, EJ. Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens. Blood/58th Annual Meeting and Exposition of the American-Society-of-Hematology 128(22), 2016. PMID: None.
98. Jain, P, Kantarjian, HM, Jabbour, EJ, Gonzalez, GN, Garcia-Manero, G, Kanagal-Shamanna, R, Patel, KP, Hu, SM, DellaSala, SE, Pierce, S, Sasaki, K, Konopleva, M, Wierda, WG, Daver, N, Kadia, TM, Borthakur, G, Estrov, Z, Ravandi, F, O'Brien, SM, Cortes, JE. Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients. Blood/58th Annual Meeting and Exposition of the American-Society-of-Hematology 128(22), 2016. PMID: None.
99. Jain, Kantarjian P, Ravandi H, Kanagal-Shamanna F, Khoury R, Patel J, Garcia-Manero K, Konopleva G, Jain M, Sasaki N, Kadia K, Borthakur T, Garris G, Pierce R, Estrov S, Z ; Wierda Z, Cortes W, O'Brien J, Jabbour S, EJ. Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens. Blood 128(22), 2016. PMID: None.
100. Kurt, H, Bueso-Ramos, CE, Khoury, JD, Routbort, M, Kanagal-Shamanna, R, Jorgensen, JL, DiNardo, CD, Ravandi, F, Kantarjian, HM, Luthra, R, Medeiros, J, Patel, K. Value of Immunohistochemistry-Based Direct Visualization for Localization, Lineage Determination and Monitoring of IDH1 p.R132H Mutant Clones in AML. Blood/58th Annual Meeting and Exposition of the American-Society-of-Hematology 128(22), 2016. PMID: None.
101. Loghavi, S, Routbort, MJ, Kanagal-Shamanna, R, Wang, SA, Khoury, JD, Ok, C, Yin, CC, Singh, RR, Zuo, Z, Bueso-Ramos, CE, Medeiros, L, Luthra, R, Patel, KP. Myeloid Neoplasms with Recurrent GNAS Mutations. Journal of Molecular Diagnostics 18(6):960-960, 2016. PMID: None.
102. Mehrotra, M, Luthra, R, Wistuba, II, Chen, W, Barkoh, BA, Montes-Moreno, S, Burns, C, Dailey, D, Bolivar, A, Routbort, MJ, Medeiros, L, Patel, KP, Singh, RR, Kanagal-Shamanna, R. "Single-Gene" Next-Generation Sequencing-Based Assay for Detection of Low-Level TP53 Mutations. Journal of Molecular Diagnostics 18(6):1047-1048, 2016. PMID: None.
103. Hodjat, Ghosh P, Priyanka K, Thakral P, Patel B, Routbort K, Kanagal-Shamana M, Yin R, Zuo C, Luthra Z, Muzzafar R, T. Mutation analysis in 35 cases of newly diagnosed therapy-related acute myeloid leukemia (AML) by next-generation sequencing (NGS): A clinicopathologic correlation. Journal of Clinical Oncology 34(15-Supplement), 2016. PMID: None.
104. Ghosh K, Hodjat P, Priyanka P, Thakral B, Patel K, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation analysis in 117 cases newly diagnosed myelodysplastic syndrome: IPSS-R high and very high risk, by next generation sequencing: association with established prognostic variables. United States and Canadian Academy of Pathology 105th Annual Meeting, 2016. PMID: None.
105. Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel K, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 50 Cases of Newly Diagnosed Acute Myeloid Leukemia arising from Myelodysplastic Syndrome by Next Generation Sequencing: A Clinico-Pathologic Correlation. United States and Canadian Academy of Pathology 105th Annual Meeting 29(2-Supplement):350A-351A, 2016. PMID: None.
106. Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel K, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation analysis in 8 cases of newly diagnosed acute myeloid leukemia arising from myeloproliferative neoplasms by next generation sequencing: a clinico-pathologic correlation. United States and Canadian Academy of Pathology 105th Annual Meeting 29(2-Supplement):351A-351A, 2016. PMID: None.
107. Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel K, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation analysis in 45 cases of newly diagnosed acute myeloid leukemia with recurrent cytogenetic abnormalities by next generation sequencing: a clinico-pathologic correlation. United States and Canadian Academy of Pathology 105th Annual Meeting 29(2-Supplement), 2016. PMID: None.
108. Quesada A, Luthra R, Patel KP, Singh RR, Routbort MJ, Loghavi S, Khoury JD, Medeiros LJ, Bueso-Ramos CE, Kanagal-Shamanna R. De novo Acute Myeloid Leukemia (AML) with RUNX1 Mutations Shows Characteristic Clinicopathologic Features. United States and Canadian Academy of Pathology 105th Annual Meeting 96:371A-371A, 2016. PMID: None.
109. Hodjat P, Ghosh K, Priyanka P, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 122 Cases of Newly Diagnosed Normal Karyotype Acute Myeloid Leukemia by Next Generation Sequencing: a Clinico-Pathologic Correlation. United States and Canadian Academy of Pathology 105th Annual Meeting 29(2-Supplement):351A-315A, 2016. PMID: None.
110. Loghavi S, Zuo Z, Doss DJ, Thompson EJ, Zhao C, Lee J, Kanagal-Shamanna R, Medeiros LJ, Bueso-Ramos CE. Bone marrow and extramedullary lesions in patients with myeloproliferative neoplasms exhibit similar miRNA profiles. Mod Pathol 29(Supp 2):360A, 2016. PMID: None.
111. Ghosh, Hodjat K, Priyanka P, Thakral P, Patel B, Routbort K, Kanagal-Shamana M, Yin R, Zuo C, Luthra Z, Muzzafar R, T. Mutation Analysis in 117 Cases Newly Diagnosed Myelodysplastic Syndrome: IPSS-R High and Very High Risk by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology/105th Annual Meeting of the USCAP 29(Supplement 2):346A-347A, 2016. PMID: None.
112. Ghosh K, Hodjat P, Priyanka P, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 200 Cases of Newly Diagnosed Myelodysplastic Syndrome By Next Generation Sequencing: Association with Established Prognostic Variables and IPSS-R. 57th ASH Annual Meeting and Exposition, 2015. PMID: None.
113. Hodjat P, Ghosh K, Priyanka P, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups. 57th ASH Annual Meeting and Exposition, 2015. PMID: None.
114. Almohammedsalim AA, Luthra R, Ok CY, Loghavi S, Mehrotra M, Abraham R, Harmon M, Lu X, Medeiros LJ, Patel KP, Kanagal-Shamanna R. Single nucleotide polymorphism-array-based comparative genomic hybridization analysis of chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of 168 cases with comparison to traditional genetic testing methods. Journal of Molecular Diagnostics/AMP 2015 17(6):773-773, 2015. PMID: None.
115. Ballester LY, Loghavi S, Kanagal-Shamanna R, Barkoh BA, Lin P, Medeiros, L, Luthra R, Patel KP. Clinical validation of a CXCR4 mutation screening assay for Waldenstrom macroglobulinemia. Journal of Molecular Diagnostics/AMP 2015 17(6):766-767, 2015. PMID: None.
116. Ok C, Loghave S, Salim AA, Chen H, Kanagal-Shamanna R, Chowdhuri SR, Broaddus RR, Lazar AJ, Rashid A, Manekia JH, Barkoh BA, Medeiros L, Singh RR, Routbort MJ, Luthra R, Patel KP. To confirm or not to confirm, that is the question for equivocal NGS findings. Journal of Molecular Diagnostics/AMP 2015 17(6):810-810, 2015. PMID: None.
117. Kanagal-Shamanna R, Luthra R, Luthra M, Lu, X, Routbort M, Jain N, Keating M, Medeiros LJ, Wierda W, Patel KP. RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia. Blood/Annual Meeting of ASH 2015 126(23), 2015. PMID: None.
118. Yabe M, Medeiros LJ, Tang G, Wang S, Bhagat G, Kanagal-Shamanna R, Bueso-Ramos C, Jorgensen JL, Chen W, Hoehn D, Lu G, Li S, Young K, Miranda R. Prognostic Factors of Hepatosplenic T-Cell Lymphoma (HSTCL): A Clinicopathologic, Immunophenotypic, and Cytogenetic Analysis of 28 Patients. Mod Pathol/USCAP 2015 28(Sup 2):389A, 2015. PMID: None.
119. Liu H, Medeiros LJ, Weisenburger D, Clemens M, Hunt K, Chai S, Amin M, Vadlamani I, Sohani A, Ferry J, Morgan EA, Parkash V, Ghagat G, L-J Y, Thomazy V, Kanagal-Shamanna R, Vasef M, Herman C, Oyarzo M, Narbaitz M, Piccolini J, Lamar W, Parter W, HughesIII C, Baptista M, Tritz D, Zhang D, Khoury J, Young K, Miranda R. Breast Implant-Associated Anaplastic Large Cell Lymphoma (Bl-ALCL): A Comprehensive Histopathological Evaluation of 40 Cases With a Proposal for a Pathologic Staging System. Mod Pathol/USCAP 2015 95(Sup 2):360A, 2015. PMID: None.
120. Kanagal-Shamanna R, Bueso-Ramos C, Singh R, Routbort M, Miranda R, Lu G, Ravandi F, DiNardo C, Kantarjian H, Medeiros LJ, Patel K, Luthra R. Next-Generation sequencing of sporadic acute myeloid leukemia demonstrates GATA2 mutation to be a secondary event frequently associated with other driver mutations. Mod Pathol/USCAP 2015 28(Supp 2):354A-354A, 2015. PMID: None.
121. Loghavi S, Kanagal-Shamanna R, Ok CY, Almohammedsalim A, Bueso-Ramos C, Routbort M, Mehrotra M, Verstovsek S, Kantarjian H, Medeiros LJ, Luthra R, Patel K. Myeloproliferative Neoplasms with calreticulin mutations exhibit distinctive megakaryocytic features and increase vascular proliferation. Laboratory Investigation/USCAP 2015 95(Sup 1):361A, 2015. PMID: None.
122. Kanagal-Shamanna R, Schlette E, Lin P, Patel KP, Wang SA, Medeiros LJ, Miranda RN, Bueso-Ramos CE. Lymphoplasmacyti lymphoma/Waldenstrom macroglobulinemia, MYD88 mutation positive in bone marrow and concurrent lymph node. 17th Meeting of the European Asso for Haematopathology 2014, 2014. PMID: None.
123. Ok C, Patel KP, Wang SA, Routbort MJ, Fu B, Singh RR, Kanagal-Shamanna R, Medeiros LJ, Luthra R. Multigene Mutational Analysis Using Next Generation Sequencing (NGS) of 484 Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). United States and Canadian Academy of Pathology, 2014. PMID: None.
124. Kanagal-Shamanna R, Luthra R, Singh R, Abraham R, Harmon MA, Mishra B, Hai S, Ho M, Medeiros LJ, Patel KP. Clinical Validation of Single Nucleotide Polymorphism Array- based Comparative Genomic Hybridization in Acute Myeloid Leukemia specimens. Association of Molecular Pathology, 2014. PMID: None.
125. Roy-Chowdhuri S, Goswami RS, Chen H, Routbort MJ, Patel KP, Aldape K, Lazar AJ, Broaddus R, Singh RR, Luthra R, Kanagal-Shamanna R. Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2) Mutations in Solid Organ Malignancies by Next Generation Sequencing. Association of Molecular Pathology, 2014. PMID: None.
126. Kanagal-Shamanna R, Singh RR, Routbort MJ, Ravandi F, Kantarjian H, Medeiros LJ, Luthra R, Patel KP. Acute myeloid leukemia with Type A NPM1 mutation is more frequently associated with FLT3 mutations compared to AML with non-type A NPM1 mutations. United States and Canadian Academy of Pathology, 2014. PMID: None.
127. Lu G, Yin CC, Abruzzo LV, Luthra R, Abraham R, Kanagal-Shamanna R, Medeiros LJ. Acquired Silent Cytogenetic Clones Arising in Patients Treated Successfully for Lymphoma. Mod Pathol 26:315-371, 2013. PMID: None.
128. Kanagal-Shamanna, R, Singh RR, Barkoh BA, Reddy NG, Patel KP, Routbort MJ, Aldape KD, Medeiros LJ, Luthra R. Multi-Gene Mutational Profiling of Acute Myeloid Leukemia Specimens on the Ion Personal Genome Machine in a Clinical Diagnostics Laboratory. J Mol Diag 15(6):867, 2013. PMID: None.
129. Kanagal-Shamanna R, Singh R, Routbort M, Aldape K, Handal B, Rahimi H, Reddy N, Barkoh B, Mishra B, Paladugu A, Manekia J, Staerkel G, Medeiros LJ, Luthra R, Patel KP. Application of Next-Generation Sequencing in Using Fine Needle Aspiration Smears and Cell Blocks from Solid Tumors. J Mol Diag 14(6):705, 2012. PMID: None.
130. Kanagal-Shamanna R, Yin CC, Muddasani R, Luthra R, Cortes J, Zuo Z, Chen SS, Hoehn D, Abruzzo LV, Miranda RN, Medeiros LJ, Lu G. Acute Myeloid Leukemia with Translocations Involving 4q12/PDGFRA: Frequent Involvement of ETV6. Mod Pathol 25:320-386, 2012. PMID: None.
131. Zhou Y, Kanagal-Shamanna R, Hoeller S, Tzankov A, Hoehn D, Swerdlow SH, Rosenwald A, Xu-Monette ZY, Miranda RN, Bueso-Ramos CE, Medeiros LJ, Young KH. Molecular Characteristics of Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Mod Pathol 25:320-386, 2012. PMID: None.
132. Kanagal-Shamanna R, Weber DM, Orlowski RZ, Lin P, Miranda RN, Bueso-Ramos CE, Medeiros LJ, Young KH. Clinicopathologic and Molecular Features of Crystal (Immunoglobulin) Storing Histiocytosis Associated with Lymphoplasmacytic Neoplasms. Mod Pathol 25:320-386, 2012. PMID: None.
133. Hoehn D, Pemmaraju N, Cortes JE, Wang X, Kanagal-Shamanna R, Dellasala SE, Nazha A, Kantarjian HM, Medeiros LJ, Bueso-Ramos CE. Dasatinib Affects Bone Homeostasis, Independent of Molecular Response, in Patients with Chronic Myelogenous Leukemia (CML). Mod Pathol 25:320-386, 2012. PMID: None.
134. Shamanna RK, Salama ME, Lehman N, Inamdar KV. Differential Expression of Aurora-A Kinase in Primary Mediastinal (Thymic) Large B-Cell Lymphoma and Classical Hodgkin Lymphoma Involving the Mediastinum. Mod Pathol 23(1s), 2011. PMID: None.
135. Kanagal Shamanna R, Medeiros LJ, Wang SA, Miranda RN. Mature B-Cell Lymphomas with Blastoid Morphology: Clinicopathologic and Genetic Features of 33 Cases. Mod Pathol 23:1s, 2011. PMID: None.
136. Kanagal Shamanna R, Medeiros LJ, Vega F. Pagetoid Reticulosis: Oral presentation (Session One). Society of Hematopathology/ European Association of Hematopathologists Workshop, 2011. PMID: None.
137. Kanagal Shamanna R, Miranda RN, Yin CC, Bueso-Ramos CE, Muddasani R, Medeiros LJ, Lu G. Clinicopathologic Study of Isolated Del(20q) in De Novo Myelodysplastic Syndrome: A Group with Favorable Prognosis and No Evidence of Common Oncogenic Mutations. Mod Pathol 23(1s), 2011. PMID: None.
138. Kanagal Shamanna R, Medeiros LJ, Miranda RN. Systemic T-cell lymphoma with secondary cutaneous involvement and phenotype switch. Oral presentation (Session Three). Society of Hematopathology/ European Association of Hematopathologists Workshop, 2011. PMID: None.
139. Kanagal-Shamanna R, Paladugu A, Barkoh B, Rahimi H, Chen SS, Sargent RL, Medeiros L, Luthra R, Patel KP. Validation of High Resolution Melting Curve Analysis (HRMA) Using Light Cycler 480 for Screening of TP53 Mutations in Human Malignancies. J Mol Diag 13(6):783-784, 2011. PMID: None.
140. Shamanna RK, Lehman N, Inamdar KV. Analysis of Aurora-A kinase expression in Hodgkin and Reed-Sternberg cells of Classical Hodgkin lymphoma: Implications in the regulation of G2/M phase of cell cycle. Mod Pathol 23(1s), 2011. PMID: None.
141. Kanagal Shamanna R, Yin CC, Lu G, Nguyen M, Hoehn D, Garcia-Manero G, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CE. Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN) with Isolated Isochromosome 17q [i(17q)]: An Aggressive Entity with Prominent Multilineage Dysplasia and Wild Type NPM1. Mod Pathol 23:1s, 2011. PMID: None.
142. Shamanna R, Zhang Z, Worsham M, Jakubowski N, Ghanem T. A 15-year perspective on pathological factors and outcomes for oral tongue invasive squamous cell carcinoma. Am J Clin Pathol/ASCP 2010 134(4):683-683, 2010. PMID: None.
143. Shamanna RK, Whiteley K, Cankovic M, Chitale D, Inamdar KV. Mutations in Exons 12-16 of the Janus Kinase 2 Gene Are Rare in JAK2V617F-Negative Chronic Myeloproliferative Neoplasms. Arch Pathol Lab Med 133(10):1710, 2009. PMID: None.
144. Shamanna RK, Meier F. Particularly Well-Demarcated Field Effect of Known Developmental Genes: A Case of Otocephaly-Agnathia Complex. Arch Pathol Lab Med 133(10):1710, 2009. PMID: None.
145. Sharma, G, RK Shamanna RK, CS Feldkamp CS, J Zajechowski and M Cosman J. Analytical Performance of Dimension Vista (R) Vitamin B12 (B12) and Folate (FOL) methods using LOCI (R) Technology. Clinical Chemistry 55(6):A231-A232, 2009. PMID: None.
146. Zhang Z, Shamanna R, Raju U, Ormsby A, Chitale D. Does Nottingham Grade, MIB-1 Labeling Index (LI) Predicts Recurrence Score (RS) of Oncotype Dx Assay. Mod Pathol/USCAP 2009 22(1s):76A-76A, 2009. PMID: None.
147. Shamanna RK, Medeiros LJ, Whiteley L, Schultz DS, Chitale DA, Inamdar KV. Aurora-A Kinase distinguishes ALK+ Anaplastic Large Cell Lymphoma from ALK negative and Cutaneous ALCL among other T-Cell Lymphomas: Analysis of 72 Cases. Mod Pathol/USCAP 2009 22(1s):286A-286A, 2009. PMID: None.
148. Shamanna RK, Lee MW, Gaba AR. Struma Ovarii with a Focus of Medullary Thyroid Carcinoma. Arch Pathol Lab Med 132(9):1501, 2008. PMID: None.
149. Shamanna RK, Zhang Z, Torres F, Lee MW. Band-Like Amyloid Deposition in Bowenoid Papulosis. Arch Pathol Lab Med 132(9):1501, 2008. PMID: None.
150. Shamanna RK, Ormsby AH, Ma CK, Linden MD, Lee MW. Comparison of Immunoprofile of Spindle Cell/ Pleomorphic Lipoma And Solitary Fibrous Tumor/ Hemangiopericytoma with CD34, CD99 And Bcl-2. Am J Dermatopathol 30(3):305-312, 2008. PMID: None.
151. Rao CP, Wellwood J, Shamanna RK, Seyfried D, Varelas P, Abdelhak T. Methemoglobinemia following awake intubation in a patient after anterior cervical discectomy and fusion. Neurocritical Care Conference, 2008. PMID: None.
152. Shamanna RK, Chitale D, Raju UB. A Ten Year Review Of 837 Cases Of Lobular Neoplasia: Association with the Spectrum of Ductal Neoplasia. Mod Pathol 21(1s), 2008. PMID: None.

Book Chapters

1. Kanagal-Shamanna R, MD & Michael H Roh MD, MD, PhD. Overview of current molecular diagnostic testing on cytology samples - Solid organ and hematological malignancies. In: Molecular Diagnostics in Cytopathology. None. Springer International Publishing, 2019.
2. Kanagal-Shamanna R. Molecular Diagnostics in Hematological Malignancies. In: Molecular Diagnostics in Cytopathology. None. Springer International Publishing, Chapter 18, 2019.
3. Kanagal Shamanna R. Digital PCR: Prinicples and Applications (Chapter 5). In: Clinical Applications of PCR/Methods in Molecular Biology (Series Title). 3. Humana Press, 2016.
4. Kanagal Shamanna R. Emulsion PCR: Techniques and Applications (Chapter 4). In: Clinical Applications of PCR/Methods Molecular Biology (Series Title). 3. Humana Press, 2016.